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Abstract 
  Respiratory tract infections are one of the leading causes of morbidity and 
mortality across the world. This is especially true for infants, young children, the 
elderly and the immunocompromised. The strain placed on economies and health 
care systems of all countries by these diseases are phenomenal. Although we are 
familiar with various agents leading to these kinds of infections (e.g. rhino-, 
influenza-, parainfluenza, human metapneumo-, respiratory syncytial-, adeno- and 
coronaviruses), the cause of a substantial portion, (48-70%) of cases remain 
unidentified (Van der Hoek et al, 2004; Fouchier et al, 2004; File, 2003; Fine et al, 
1999; Shay et al, 1999, Henrickson et al 2004; Murray et al 2001).  
In the past, human coronaviruses have not been known to cause severe 
disease in humans. For this reason, little research was performed on these viruses, 
with research focusing on the animal coronaviruses that are of veterinary 
importance. However, with the outbreak of SARS in 2003, the field of human 
coronavirus research has received significantly more attention. Also, the subsequent 
identification of two additional novel human coronaviruses (NL63 and HKU1) has led 
to an increased awareness of the potential threat of these viruses. With the 
discovery of these new human coronaviruses, it has become clear that the potential 
for another outbreak by a yet unknown human coronavirus is a very real possibility. 
This has made research into the pathogenesis and the role of the various 
coronavirus genes in the pathogenesis of these viruses of utmost importance.    
HCoV-NL63 was first discovered in January 2003 in the Netherlands. It 
causes upper and lower respiratory tract disease in young children, the elderly and 
immunocompromised individuals. The disease is also associated with croup and has 
x 
even been implicated as a possible cause of the childhood vascular ailment 
Kawasaki Disease. HCoV-NL63 is frequently found in combination with other 
respiratory viruses leading to superinfections. It is still unclear whether HCoV-NL63 
is an opportunistic virus or whether it leads the way for co-infection with other 
respiratory viruses. This particular virus is also the only coronavirus sharing the 
same cellular receptor as SARS-CoV.  
The virus is found all over the world and has been identified in countries like 
Australia (Arden et al, 2005), Japan (Ebihara et al.,   2005; Suzuki et al.,  2005), 
Belgium (Moës et al.,  2005), Hong Kong (Chiu et al.,  2005), Taiwan (Wu et al.,  
2007) Korea (Choi et al.,  2006), Canada (Bastien et al.,  2005), France (Vabret et 
al.,  2005), Switzerland (Kaiser et al.,  2005; Garbino et al.,  2006), Germany (Van 
der Hoek et al.,  2005), Sweden (Koetz et al.,  2006) and South Africa (Smuts and 
Hardie, 2006). 
In this study, the HCoV-NL63 genome was transcribed from RNA to DNA from 
which the M gene was amplified with various primers designed for use in specific 
expression systems. The various genes were cloned into the pGEM vector and 
confirmed by sequencing. The genes were now expressed in cloning vectors suited 
for each expression system (pFastBac for baculovirus expression, pFlexi for 
bacterial expression and pCMV for mammalian expression). Clones were sequenced 
for a second time. The recombinant clone in pFlexi was expressed in KRX cells and 
a 36hr time course was performed. The recombinant pFastBac clone was used to 
infect Sf9 insect cells and P1 and P2 viral stocks were obtained. The recombinant 
pCMV clone was used to transfect Cos1 mammalian cells. 
 
xi 
The genome was successfully transcribed and the M gene amplified and 
cloned into pGEM and confirmed by sequencing. Subsequent cloning of the various 
M genes into pFastBac for baculovirus expression, pFlexi for bacterial expression 
and pCMV for mammalian expression was achieved and sequencing confirmed the 
presence of the inserts in frame. 
pFlexi clones were successfully expressed in bacterial KRX cells with 
expression of the M protein in the pellet of the lysed bacterial cells. No M protein was 
seen in the supernatant of the lysed cells. Sf9 insect cells were infected with the 
recombinant pFastBac clones and P1 and P2 viral stocks were obtained. Protein 
expression occurs in KRX bacterial cells with optimal expression at approximately 24 
hours. The M protein expresses on the cell membrane as can be concluded from the 
product obtained in the pellet of the lysed bacterial cells. Very little of the expressed 
protein is present in the plasma of the cell as evidenced by the absence of protein in 
the supernatant of the lysate.  
 
xii 
Publication of Research 
Oral and poster presentations 
L Lubbe, R Fisher, T Suliman and BC Fielding, Molecular biology of human  
coronavirus NL-63, 186th General Meeting of the Experimental Biology Group 
(EBG), University of the Western Cape, 30th October 2008. (Invited Oral 
presentation) 
L Lubbe and BC Fielding, Expression studies of human coronavirus NL63 M 
protein, 16th Annual Faculty of Natural Sciences Research Open Day, University 
of the Western Cape, 27-28 October 2008. (Oral presentation) 
L Lubbe, S. Khan and BC Fielding, Cloning of human coronavirus NL63 M 
protein for expression in a baculovirus system, Medical Research Council 
Research Day, MRC Conference Centre, Parow Valley, 16-17 October 2008. 
(Poster presentation) 
L Lubbe and BC Fielding, Expression studies of human coronavirus NL63 M 
protein, Medical Biosciences Seminar Series, University of the Western Cape, 11 
September 2008. (Oral presentation) 
 
Abstracts 
L Lubbe and BC Fielding, Expression studies of human coronavirus NL63 M 
protein, 16th Annual Faculty of Natural Sciences Research Open Day, University 
of the Western Cape, 27-28 October 2008. (Abstract book) 
xiii 
L Lubbe, S. Khan and BC Fielding, Cloning of human coronavirus NL63 M 
protein for expression in a baculovirus system, Medical Research Council 
Research Day, MRC Conference Centre, Parow Valley, 16-17 October 2008. 
(Abstract book) 
 
Awards 
 Deutscher Akademischer Austausch Dienst (DAAD) Scholarship, 2008 
xiv 
Acknowledgements 
I would like to thank my supervisor Prof. B. C. Fielding for all the support and advice 
throughout the entire project. I also take this opportunity to thank my colleagues 
Randall Fisher and Tasnim Suliman for all their help and encouragement. Various 
other people helped make this project a reality and have my heartfelt gratitude. Prof 
Sehaam Khan and her students (for the use of her laboratory and expertise on 
baculovirus protocol), Peter Witbooi (my faithful bodyguard during late night lab 
experiments), Hannes Ehlers (for patiently helping with hours of image editing), my 
parents (for endless belief and encouragement in the most frustrating of times) and 
last but certainly not least, Martin Immelman for all the love, patience and litres of red 
wine involved in a fiancé writing a thesis.   
 
  
 
 
Chapter 1: Introduction  
Chapter 1: Introduction 
2 
1.1. Background 
Respiratory tract infections are one of the leading causes of morbidity and 
mortality across the world and according to the World Health Organization (WHO, 
2003), lower respiratory tract infections (LRTI) account for up to 20% of all deaths in 
children under five. Not only does it cause substantial mortality in the elderly, infants 
and young children, but it is also the most common cause of hospitalization and 
antibiotics usage in immunocompromised individuals and those with chronic lung 
diseases. Although we are familiar with various agents leading to these kinds of 
infections (e.g. rhino-, influenza-, parainfluenza, human metapneumo-, respiratory 
syncytial-, adeno- and coronaviruses), the causative viral agents of a substantial 
portion (48-70%) of cases remains unidentified (Fouchier et al, 2004; Henrickson et 
al 2004; Van der Hoek et al, 2004; File, 2003; Murray et al 2001; Fine et al, 1999; 
Shay et al, 1999). The strain placed on economies and health care systems of all 
countries by these diseases are phenomenal. This is especially true for South Africa 
and similar countries with an increasing number of immunocompromised individuals 
due to the HIV/AIDS pandemic. No studies have yet been undertaken in South Africa 
to ascertain the effec human coronavirus NL63 (HCoV-NL63) might have on the high 
risk individuals.  
Human coronavirus (HCoV)-229E and HCoV-OC43, both discovered in the 
mid 1960’s (Hamre & Procknow, 1966; Tyrrell & Bynoe, 1965) are considered as the 
so called “common cold” viruses (Bradburne and Somerset, 1972; Bradburne et al., 
1967; Hamre & Procknow, 1966). It is believed that they are responsible for up to 
30% of all common colds (McIntosh, 1996), often resulting in mild and self-limiting, 
mostly upper respiratory tract infections (McIntosh, 1996).  
During the past six years three “new” human coronaviruses have been 
identified. In early 2003 the causative agent of severe acute respiratory syndrome 
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(SARS) was identified as the novel coronavirus SARS-CoV (Drosten et al., 2003; 
Ksiazek et al., 2003). This virus causes severe respiratory disease characterized by 
atypical pneumonia. Up to 10% of infections are fatal and the disease resulted in the 
loss of about 800 lives before being brought under control late in 2003 (Peiris et al 
2003; Stadler et al, 2003; WHO, 2003).  It is speculated that the virus was 
transmitted in a zoonotic event from bats to civet cats (prepared as food source in 
China), and ultimately to humans (Lau et al., 2005; Li et al., 2005).  
As a result of all the attention focused on the field of coronavirology brought 
about by the outbreak of SARS, another two human coronaviruses were 
subsequently identified, namely HCoV-NL63 and HCoV-HKU1. HCoV-HKU1 is the 
most recently discovered human coronavirus; it was isolated and identified in 
January 2005 in Hong Kong from a 71 year old man with chronic pulmonary disease 
(Woo et al, 2005). The virus causes common cold-like symptoms and other acute 
respiratory tract infections and may also cause febrile seizures in up to 50% of 
cases. Typically, HCoV-HKU1 infects children, but can sometimes also infect 
immunocompetent adults (Woo et al., 2005). 
HCoV-NL63 was first isolated in January 2003 in Amsterdam, Netherlands at 
the Amsterdam Medical Centre. It was isolated from a nasopharyngeal aspirate 
(NPA) of a 7 month old hospitalized child presenting with coryza, fever, brochiolitis 
and conjunctivitis. The specimen from this patient tested negative for all the known 
respiratory viruses. It was then inoculated into a tMK cell line followed by inoculation 
into LLC-MK2 cells. The novel NL63 virus was identified from the supernatant using 
the VIDISCA method. Sequencing showed that this virus was related to the 
coronaviruses (with 42-81% sequence homology to HCoV-229E) but was indeed a 
new member of the virus coronavirus family as opposed to a recombinant member 
(Van der Hoek et al., 2004). 
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In 2004, another group at the Erasmus Medical Centre in the Netherlands 
described this virus found in a nose swab taken from an 8 month old pneumonia 
patient from 1988. They cultured the virus in Vero-E6 instead of LLC-MK2 cells and 
identified the virus in the supernatant. They named their virus HCoV-NL. The 
sequence of this virus corresponded 98.8% at nucleotide level with that of the virus 
discovered by Van der Hoek et al. (2005) and it was subsequently concluded that 
they represent the same virus (Fouchier et al.,  2004). Esper et al. (2005) discovered 
a virus at the Yale University in New Haven in 2005 that had a 94-100% homology 
with the two previously discovered viruses. Even though they named the virus 
HCoV-NH this virus was also concluded to be the same virus as those discovered by 
Van der Hoek et al. (2005) and Fouchier et al. (2004).   
Even though three groups stumbled upon this virus in the space of a year, this 
might in fact not be the first time that this virus was isolated. In the mid 1960’s, 
human coronaviruses were cultured in human embryonic tracheal organ cultures. 
These viruses seemed to be only distantly related to HCoV-229E and HCoV-OC43 
(Macintosh et al, 1967; Tyrrell & Bynoe, 1965). Then in the early 1980’s, more 
human coronavirus isolates were obtained from cell or organ culture and extensively 
studied by Larson et al. (1980) and Macnaughton et al. (1981). Some of these 
isolates were serologically related to the group II HCoV-OC43 while others were 
serologically related to the group I HCoV-229E. Some of the group I isolates could 
be cultured in MRC continuous cells like HCoV-229E while others could only be 
cultured in human foetal tracheal and nasal organ culture cells – very much like 
HCoV-NL63. Unfortunately these cultured strains were lost to science before this 
could be further investigated. Up to this day it can only be speculated whether this 
was the first observed strains of HCoV-NL63, HCoV-HKU1 or a still undiscovered 
human coronavirus. 
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1.2. Coronaviruses 
The order Nidovirales consists of the viral families Arteriviridae, Roniviridae 
and Coronaviridae (Cavanagh, 1997). The Coronaviridae family has been further 
divided into two subfamilies  namely toroviruses and coronaviruses (Figure 1) 
(Nidovirus Symposium, 2005). 
Traditionally, coronaviruses have been divided into 3 groups according to 
genome sequence, host preference and serological cross-reactivity (Holmes, 2001). 
Group 1 and 2 coronaviruses cause respiratory, central nervous system and enteric 
disease in humans and mammals (Guy et al., 2000; Holmes and Lai, 1996). They 
have been isolated from mice, rats, pigs, dogs, cats, rabbits, horses and cattle 
(Holmes and Lai, 1996). Group 1 includes coronaviruses such as transmissible 
gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV) and feline 
infectious peritonitis virus (FIPV). Also, included in Group 1 are the human 
coronaviruses 229E, and NL63. Group 2 includes three human coronaviruses – 
OC43, HKU1 and severe acute respiratory coronavirus (SARS-CoV), as well as 
several animal coronaviruses like murine hepatitis virus (MHV), bovine coronavirus 
(BCoV), porcine heamagglutinating encephalomyelitis virus (PHEV), rat 
sialodacryoadenitis coronavirus (SADV) and equine coronavirus (ECoV). Group 3 
coronaviruses only infect avian hosts (Holmes and Lai, 1996) and have been shown 
to infect chickens, pigeons, geese, ducks and turkeys and include infectious 
bronchitis virus (IBV), turkey coronavirus (TCoV) and pheasant coronavirus 
(PhCoV).  
 
Chapter 1: Introduction 
6 
 
 Figure 1. Classification of Human Coronavirus-NL63 (Nidovirus Symposium, 2005) 
 
1.2.1. Basic structure 
The name coronavirus was first used in 1968 and originates from the crown 
like appearance of these viruses when viewed under an electronmicroscope (Tyrrell 
et al, 1968). They are round/pleiomorphic viruses roughly 80-120nm in diameter 
(Figure 2). They are enveloped RNA viruses with the largest genomes found in all 
RNA viruses – 27-33 kb (Masters, 2006). Within the viral membrane there is a helical 
capsid, which is made up of RNA complexed with the nucleocapsid (N) protein. The 
membrane also contains three more proteins - spike (S), the membrane (M) and the 
envelope protein (E). These four proteins are the essential proteins and are found in 
all coronaviruses. There are also some non-essential proteins that are characteristic 
to certain groups. Some group 2 species has a unique protein known as the 
heamagglutinin esterase (HE) as well as the internal (I) protein (Pyrc et al., 2004; 
Siddell, 1983). SARS has the ORF3a protein – an additional structural protein. 
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Figure 2. General structure of HCoV-NL63  
 
1.2.2. Genome structure   
Coronaviruses have linear, non-segmented, positive-sense, single stranded 
RNA genomes. The genomes of about 30 kb are capped and polyadenelated. The 5’ 
end has an untranslated region of 286 nucleotides and the 3’ end has an 
untranslated region of 287 nucleotides (Van der Hoek et al., 2004). 
Coronavirus genomes consist of two distinct regions, with a typical gene 
arrangement (Figure 3). The 5’ two thirds of the genome codes for the proteins 
needed for RNA synthesis. The 3’ third of the genome codes for 5 structural proteins 
in the conserved order, 5’-membrane (M)-spike (S)-nucleocapsid (N)-envelope (E)-
3’. Interspersed among the structural genes coronavirus genomes contain genes that 
encode for accessory proteins. These non-essential accessory genes vary greatly in 
position and number in the different coronavirus species. The function of these 
proteins is not yet fully understood, but they are thought to contribute to virus 
pathogenicity, possibly interfering with the innate immune response of the host.  
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 Figure 3. Genome structure of HCoV-NL63 
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1.2.3. Structural proteins 
1.2.3.1 Spike protein (S) 
The S protein is a type I glycoprotein that protrudes from the virus surface and 
provides the virus with its characteristic crown-like appearance (Bosch et al., 2003). 
During processing of the protein in the Golgi apparatus, the spike is cleaved into the 
S1 and S2 subunit each approximately 90 kDa (Sturman and Holmes, 1977). In the 
globular head of the S1 protein there is a receptor binding domain located in the first 
330 amino acids (Kubo et al., 1994). The S2 subunit is anchored in the membrane 
and has 2 heptad repeat regions (HR1 and HR2) (Van der Hoek et al., 2006) which 
are longer than coronaviruses of group II and III (Bosch et al., 2004). This extra 
length is due to the 14 amino acid insert present in 2 extra helical turns. After 
infection of the cell, the HR1 and HR2 polypeptides will fuse into a stable 6 helix 
bundle (Pyrc et al., 2006). S2 also has a transmembrane domain. It is thought that 
this protein has a role in infection of target cells, cell to cell spread and may also play 
a role in the replication cycle of the virus. Even though the S protein of NL63 is very 
similar to other type 1 glycoproteins, it differs in the aspect of not needing to be 
cleaved into the two parts to be able to infect a cell (de Haan et al., 2004). Another 
unique feature is the 179 amino acid domain it has at the N terminal part of the 
spike. This sequence contains several glycosylation sites and is thought to play a 
role in the evasion of the host’s immune response (Van der Hoek et al., 2006). The 
virus attaches to a cellular receptor via its S protein. This causes a conformational 
change in the cell allowing fusion of the viral and cellular membranes (Matsuyama 
and Taguchi, 2002; Saeki et al., 1997).  
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1.2.3.2. Nucleocapsid protein (N) 
The N protein has a role in pathogenesis as well as transcription. Without this 
protein, the virus cannot be effectively recovered from infectious cDNA clones (Yount 
et al., 2003; Yount et al., 2002). While the N protein has not been studied in depth for 
the NL63, other coronaviruses of all 3 groups have the N protein localized in the 
nucleolus and cytoplasm. This could be an indication that the protein may delay or 
arrest the cell cycle in the G2/M phase. It most likely achieves this by inhibiting 
cytokines (Wurm et al., 2001).  
 
1.2.3.3. Envelope protein (E) 
The E protein of some coronaviruses can form virus like particles when 
expressed with or without the M protein and therefore plays a vital part in the 
assembly and infectivity of the virus (Kuo and Masters, 2003; Vennema et al., 1996). 
This protein can also induce apoptosis in certain cells via the caspase dependant 
pathway (An et al., 1999). This apoptosis may be the cause of the lymphopaenia 
commonly found in SARS positive patients (Young et al., 2005). SARS-CoV E 
proteins have been shown to have cation selective ion channel activity of which the 
role has yet to be fully established. It has been speculated that the channel could be 
important for the budding, morphogenesis and assembly of the virus (Wilson et al., 
2004).  
 
1.2.3.4. Membrane protein (M) 
The M protein is the most abundant of the coronavirus membrane proteins. It 
is a type III glycoprotein consisting of three parts, a short ectodomain at the N-
terminal, a triple membrane spanning region and a cytoplasmic tail (Bond et al., 
1979). It has been hypothesized that the membrane of the coronavirus consists of a 
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dense matrix of laterally interacting M proteins (de Haan et al., 2000). The proteins 
are found in complexes in the Golgi apparatus when they are expressed on their own 
(Krijnse Locker et al., 1995).  
The M protein has been shown to be N-glycosylated (de Haan et al., 2003). 
Some coronavirus M proteins, like that of TGEV, have proven to have interferogenic 
activity. It was also shown that if there are mutations in the ectodomain of the M 
protein causing impairment of the N-glycosylation, the interferogenic activity of these 
viruses will be down regulated (Laude et al., 1992). Studies on MHV have shown 
that the glycosylation state of the M protein does not affect the virus’ ability for in 
vitro replication. It does however, have an effect on the protein’s ability to replicate in 
vivo in the liver, as well as its ability to induce IFN-α in vitro (de Haan et al., 2003). It 
also has an effect on the interaction with host cells.  
As for the general function of the M protein, it is believed to play a role in the 
assembly of the virion as well as in interaction with host cells and therefore 
infectivity. The formation of new virions is dependent on two processes. The one is 
the assembly of the nucleocapsid and the other, the assembly of the envelope. The 
M protein plays an essential role in both these processes by directing the formation 
of the envelope as well as providing the basis for the attachment of the nucleocapsid 
to enable budding (de Haan et al., 2000).  
The interaction of the M protein with other proteins has been studied by using 
the method of production of viral-like particles (VLP’s). By expressing the M protein 
and any other protein together, the minimal interactions required for the formation of 
the particles resembling the original virus, can be determined. (Bos et al; 1996, 
Vennema et al; 1996).  The M gene is vital in the formation of these VLP’s. This is 
proven by the fact that the ability of a virus to produce these VLP’s is majorly 
affected with mutation of the M gene (de Haan et al; 1998). This is true even when 
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there are only two amino acids removed from the carboxy terminal end of the 
protein. A mutation like this in fact proved to be lethal (Kuo et al; 2002).  
The M protein does not only interact with the host molecules but also with 
other proteins within the virus itself. The interaction of the M protein with the E 
protein has been well documented and is believed to be the most important step in 
the viral assembly process. When the genes for these two proteins were expressed 
in cells, VLP’s were formed. These particles were nearly identical in size and shape 
to the original viruses. In some studies it was shown that the M protein interacts with 
the N protein in vitro as well as in vivo (Kuo and Masters, 2002; Escors et al, 2001; 
Narayanan and Makino, 2001). This interaction is key to the assembly of the virus as 
it lacks the structural matrix protein of other enveloped viruses (He et al, 2004). 
Further down the line in the process of virion assembly, the M protein also interacts 
with the RNA packaging signal to form the mature packaged virus particle 
(Narayanan et al, 2003). The interaction between the M protein and the S protein 
also seems to be an essential step in the assembly of the virus (Rottier, 1995).  
The uniqueness of the M protein is further highlighted by its ability to induce antibody 
production in hosts either during infection or inoculation with attenuated viral 
vaccines. This takes place in spite of the fact that the greater part of this protein is 
buried within the viral membrane (Wesseling et al, 1993; Vennema et al, 1991; 
Pulford and Britton, 1991; Laude et al, 1986; Fiscus and Teramoto, 1987). This 
ability is useful for the production of vaccines and utilization as a target for diagnostic 
tests. This immunogenicity is due to two immunodominant epitopes situated one 
each at the N terminal and the C terminal of the M protein as shown by He et al 
(2005) for the SARS virus. They found that the epitope at the N terminal was very 
immunogenic when introduced into patients but less so when introduced into 
immunized animals. The opposite was true for the epitope at the C terminal. This 
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phenomenon highlights the difference in immunogenic properties of the epitopes in 
immunization and infection. It is believed that the N terminal epitope is the major 
immunogenic epitope (He et al, 2005).  
The HCoV-NL63 structural genes, their sizes, functions and locations are 
summarised in Table 1. 
 
Table 1. Summary of structural genes of HCoV-NL63  
Gene Protein Size (approx 
kDa) 
Function Location 
M Membrane 26 Virus assembly, host 
interactions, interferogenic 
activity 
Membrane 
E  Envelope 10 Virus assembly, apoptosis, 
cation selective ion 
channel activity 
Membrane 
ORF3  ORF3 26 Unknown Membrane 
N  Nucelocapsid 42 Pathogenesis and 
transcription 
Cytoplasm 
S  Spike 150-200 Infection of target cells, 
cell to cell spread, role in 
replication, evasion of host 
immune response 
Membrane 
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1.2.4. Replication and life cycle   
It is commonly known that RNA viruses have extremely high mutation rates – 
up to one mutation per replication cycle (Moya et al., 2004; Drake and Holland, 
1999). This leads to the quasispecies concept that says that RNA viruses can exist 
as a dynamic distribution of variants within a closely related, yet non-identical 
genome centered on a master sequence (Domingo, 2002). HCoV-NL63 also has a 
high frequency of recombination because of its unique method of replication. This is 
due to the switching of random templates during RNA replication. This mechanism is 
called the “copy choice” mechanism (Herrewegh et al., 1998; Lai et al., 1985). These 
features allow high mutation rates enabling these viruses to adapt to new 
circumstances and hosts very rapidly.  
When the virus meets the target cell, it attaches to the ACE2 receptor with its 
spike protein. The spike is divided into S1 and S2 parts. The S1 part is situated at 
the amino terminal end and contains the receptor binding domain. The S2 part is 
situated at the carboxy terminal end of the spike and has the fusion peptide, a 
membrane spanning region and two heptad repeat regions – HR1 and HR2 (Van der 
Hoek et al., 2006). This binding of the spike with the ACE 2 molecule causes a 
conformational change to occur in the spike protein leading to the fusion of the viral 
and target cell membranes (Figure 4). The nucleocapsid of the virus can now be 
released into the target cell (Matsuyama and Taguchi, 2002; Saeki et al., 1997).  
 The first event after release of the viral nuclear material is replication of the 
viral genome. The 1a and 1b genes at the 5’ end of the genome are translated into 
their respective polypeptides pp1a and pp1ab directly from the genomic RNA. The 
translation of pp1ab can only occur if there is a -1 ribosomal frameshift. This occurs 
via a slippery sequence in a potential RNA pseudoknot in the RdRp gene. The knot 
has an 11 base pair stem forming a hairpin with an 8 nucleotide loop.  
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Figure 4. Life cycle of coronaviruses (Groneberg et al., 2005) 
 
A sequence 167 nucleotides downstream of this pseudoknot form five base 
pairs with the loop to complete the structure. The slippery sequence is a sequence of 
seven nucleotides (UUUAAAC) slightly upstream of the pseudoknot. 
The expression of the regulatory proteins is controlled by posttranslational 
enzymatic processing. A multisubunit is constructed under the influence of various 
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enzymes that cleave the 1a and 1b protein. This subunit is responsible for replication 
and transcription. Open reading frame (ORF) 1a codes for the papain-like protease 
PLpro and a serine-like protease Mpro. These proteases cause cleavage of the 1a/1b 
polypeptide. Various other enzymes are coded for and produce to help with 
regulatory functions. ORF1b codes for a RNA dependant RNA polymerase (RdRp) 
and helicase as well as a putative 3’-5’ exonuclease (ExoN), poly(U)-specific 
endoribonuclease (XendoU) and putative S-adenosylmethionine-dependant ribose 
2’-O-methyltransferase. These enzymes may also play a role in viral metabolism and 
in interference of the host cell metabolism. 
For the creation of the structural proteins, a set of subgenomic RNAs are 
made. These include subgenomic RNAs for the spike, membrane, envelope, 
nucleocapsid and ORF3. All of these subgenomic RNAs have an untranslated leader 
sequence of 72 base pairs. These sequences are identical and are derived from the 
amino terminal end of the genomic RNA. The exact mechanism whereby these 
subgenomic RNAs are created is not entirely clear but it is thought to involve an 
inimitable method of discontinuous transcription.  
During the negative strand synthesis there is a halt at the transcription 
regulatory sequence (TRS). There is a base pairing between the cis-acting TRS in 
the 5’ end of the viral genome and the TRSs upstream of each of the other ORFs. 
This leads to a chain transfer event taking place whereby the nascent RNA chain 
switches from the regulatory sequence on the negative strand to one situated in the 
5’ untranslated region of the genome. Antileader sequences are added to the 3’ ends 
of all the negative strand RNAs (AACUAAA). These antileader sequences can now 
serve as the templates for the synthesis of mRNAs and are highly conserved in all of 
these subgenomic RNAs. The only exception to this rule is in the subgenomic RNA 
of the E protein. It is thought that this protein has an unfavourable antileader 
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sequence of AACUAUA. For this reason this amount of subgenomic mRNA is less 
than for the mRNAs of the other proteins with normal antileaders. The most profuse 
subgenomic mRNA is that of the N protein and has inverse proportionality between 
the distance of a gene to the 3’ untranslated region and its RNA expression level. 
Translation of the structural proteins of the virus can now take place. This happens 
mostly exclusively from the 5’ ORF.  
Posttranslationally, the membrane and envelope proteins move to the Golgi 
intracellular membranes and are situated close to the endoplasmic reticulum Golgi 
intermediate compartment. This is the proposed site from where the virus will 
eventually bud off. There are various proteins involved in the process budding but 
even in their absence M and E combined will still form virus-like particles. The spike 
will locate itself on both the plasma and the intracellular membranes from where it 
will interact with M during virus assembly. N protein will complex with the genomic 
RNA again to form the original helical structures and will also interact with the M 
protein. Vesicles are formed into which the virus can bud. These vesicles will move 
to the surface of the cell from which it will be released. 
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1.3. Human Coronavirus NL63 (HCoV-NL63) 
 
1.3.1. Virus cell entry 
As HCoV-NL63 shares 56% amino acid homology with its closest relative 
229E (Fouchier et al., 2004; Pyrc et al., 2004; Van der Hoek et al., 2004), one would 
assume that the virus will use the same receptor (aminopeptidase N/CD 13) for entry 
(Delmas et al, 1992; Yeager et al, 1992). It has, however, been shown that NL63 
does not use this receptor for cell entry at all (Hofmann et al., 2005). The reason for 
this being that the NL63 virus has a unique 179 bp sequence at the N-terminus (Van 
der Hoek et al, 2004). With the use of a technique employing pseudovirions, 
Hofmann et al (2005) showed that this virus is able to use the zinc metalloprotease 
angiotensin-converting enzyme (ACE) 2, a characteristic it shares with the SARS 
coronavirus (Li et al.,  2003). The ACE2 receptor and the ACE protein are 
homologues of each other, both of which plays a vital role in controlling the renin-
angiotensin system (Rice et al, 2004, Danilczyk et al, 2003, Crackower et al, 2002). 
The ACE2 molecule is found on the arterial and venous endothelium, epithelium of 
the small intestine, arterial smooth muscle cells and on the surface of ciliated cells of 
human nasal and tracheobronchial epithelium (Sims et al., 2005; Hamming et al., 
2004). In the lung this system plays an important role in acute lung injury when it is 
activated (Imai et al., 2005). ACE is responsible for the activation of the system by 
the cleavage of the angiotensin I into angiotensin II. ACE 2 on the other hand 
protects the lungs by inactivating angiotensin II and therefore halting the damage 
caused by ACE. During SARS infection, it is thought that the virus partially inhibits 
the expression of ACE2 and that this in part the reason for the severe lung failure 
(Kuba et al., 2005). Considering that the action of SARS and NL63 both has the 
same effect on this system, it would appear incongruent that HCoV-NL63 has such a 
Chapter 1: Introduction 
19 
mild pathogenicity in comparison. This might suggest that this binding and inhibition 
of expression of ACE 2 is not the only event in determining the severity of these two 
viruses and thus warrants further investigation (Van der Hoek et al., 2006). 
 
1.3.2. Culturing in permissible mammalian cell lines 
The receptor usage of a virus also inevitably determines which cell lines and 
hosts the virus can use for replication (Kuo et al, 2000; Holmes, 1996). To determine 
which cells are suitable for HCoV-NL63, Schildgen et al  (2006) tested six cell lines 
that are routinely used for viral culture. The lines they tested included Human lung 
fibroblasts (MRC-5: ATCC-CCL-171), rhabdomyosarcoma cells (A-204; ATCC-ACC-
250), Madin-Darby-Canine-kidney cells (MDCK: ATCC-CCL-34), monkey kidney 
cells (Vero-B4 cells: ATCC-ACC-33; LLC-MK2 cells: ATCC-CCL7), and laboratory 
adapted non-ATCC-listed monkey kidney cell line monkey stable (MS). Supernatant 
of the cell culture were sampled and the RNA was extracted and virus yield 
determined by polymerase chain reaction (PCR). The cells were also monitored for 
cytopathic effect (CPE).  
The cell lines found to be permissive for HCoV-NL63 were the monkey kidney 
cell lines LLC-MK2 and Vero-B4. The titers of the virus increased up to 4000 fold in 
these cell lines. The rise in titers of the other cell lines was negligible. All cell lines 
showed CPE except the human lung fibroblasts. The fact that these cells (MDCK, 
MS and RD) showed CPE but no increase in viral titers may be due to the 
inoculation of NL63 being toxic to these cells initially. It could also be that these cell 
lines are simply not able to secrete the virus particle into the supernatant and 
therefore appear not to have a rise in titers. Regardless of the reason, these cells are 
not seen as being sustainable for the culture of HCoV-NL63.  
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Other studies have shown that there are other cell lines that are also 
permissive for infection from this virus. An example would be the human 
hepatocellular carcinoma cell line Huh-7, another characteristic NL63 shares with 
SARS (Hofmann et al., 2005).   
The question might arise as to why this virus was not previously discovered if 
it can then be cultured in routine laboratory cell lines. The reason being that the only 
parameter being routinely checked for the presence of viruses in cell lines is the 
observation of CPE. The CPE observed for NL63 appears to be identical to picorna 
viruses and may therefore have been observed before but have been mistaken for 
these known viruses (Schildgen et al., 2006)  
Even though coronaviruses can be cultured, they do not always grow very 
well and they are not easy to isolate and study. The failure to previously detect these 
viruses is due to unreliable methods that are time consuming and not sensitive 
enough. The unavailability of proper lower respiratory tract specimens further 
hampered the discovery of these new viruses. The most common methods currently 
being used for detection of these viruses include viral culture and direct 
immunofluorescence and more recently molecular methods like reverse transcription 
(RT) PCR (Vabret et al, 2001). Even though viral culture has been considered the 
gold standard, it can only detect small numbers of viruses and results depend greatly 
on quality of sampling, storage, transport and type of cells used. It also takes several 
weeks and can therefore not be used as a diagnostic tool. Direct 
immunofluorescence results are more rapid and have been shown to improve patient 
outcome with less antibiotic use and shorter hospital stays (Barenfanger, 2000; 
Adcock et al, 1997; Woo et al, 1997). Vijgen et al have now developed a new one-
step real-time quantitive reverse transcriptase PCR assay for HCoV OC43 and 229E 
that is even more reliable, sensitive and time efficient for detection of these 
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respiratory viruses (Vijgen et al, 2005). Recently Moës et al adapted this technique 
to detect HCoV-NL63 (Moës et al, 2005). 
 
1.3.3. Clinical infection, symptoms and prevalence  
This virus causes not only upper respiratory tract infection but also lower 
respiratory tract infection and can even cause pneumonia (Bastien et al., 2005; 
Vabret et al., 2005). General symptoms of infection with NL63 can include any of the 
following: fever, cough, coryza, rhinorrhoea, pharyngitis, sore throat, hoarseness, 
bronchitis, bronchiolitis, pneumonia, and croup (Arden et al.,  2005; Bastien et al.,  
2005; Chiu et al., 2005; Moës et al., 2005; Vabret et al.,2005; Fouchier et al., 2004; 
Konig et al., 2004; Forster et al., 2004). 
Since its discovery in the Netherlands, various research groups have found 
this virus in countries all over the world. These countries include Australia (Arden et 
al, 2005), Japan (Ebihara et al., 2005; Suzuki et al., 2005), Belgium (Moës et al.,  
2005), Hong Kong (Chiu et al.,2005), Taiwan (Wu et al., 2007) Korea (Choi et al.,  
2006), Canada (Bastien et al., 2005), France (Vabret et al., 2005), Switzerland 
(Garbino et al., 2006; Kaiser et al., 2005), Germany (Van der Hoek et al., 2005), and 
Sweden (Koetz et al., 2006). This shows that this virus occurs all over the world in 
tropical, subtropical and temperate countries (Table 2). The virus has shown a 
seasonal prevalence especially in the temperate countries where it preferred the 
colder climate in winter, a characteristic it shares with HCoV-229E and HCoV-OC43 
(Arden et al. 2005; Bastien et al., 2005; Ebihara et al., 2005; Moës et al., 2005; 
Vabret et al., 2005; Van der Hoek et al., 2005 Hendley et al.,1972). In the subtropical 
and tropical areas the virus was more prevalent in the early spring (Chiu et al., 
2005). 
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Table 2. Seasonal prevalence of HCoV-NL63  
Country Positive samples Percentage Seasonality 
Australia 16/766 2.1 Winter 
Belgium 7/279 2.3 Winter 
Canada 45/1765 2.5 Winter 
France 28/300 9.3 Winter 
Germany 49/949 5.2 Winter 
Hong Kong 15/587 2.6 Spring 
Japan 5/419 1.2 Winter 
Switzerland 6/82 7.0 Winter 
 
 
As stated previously, HCoV-NL63 affects the young and the elderly but it has 
been shown in all these studies that the prevalence for infection is highest in children 
under five years old. It also more frequently infects the elderly and 
immunocompromised adults and often leads to hospitalization due to severity. 
Many studies have been performed (Table 3) to ascertain how frequent NL63 
infection is in comparison with other human coronaviruses commonly known to 
cause respiratory disease (Chiu et al., 2005; Kaiser et al. ,2005; Moës et al., 2005; 
Vabret et al., 2005; Van der Hoek et al., 2005). Based on the results, it is clear to see 
that this virus causes a substantial amount of infections when compared to its 
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relatives in other groups. Moës et al (2005) showed that of all the human 
coronaviruses it is NL63 and OC43 that causes the most hospitalization.  
 
Table 3. Frequency of NL63 in comparison to other human coronaviruses 
Country Specimens % NL63 % 229E % OC43 
Belgium 309 2.3 0.3 4.7 
France 300 9.3 0 2.2 
Hong Kong 587 2.6 0.3 1.5 
Netherlands 63 4.7 0 7.7 
Switzerland 82 7.3 3.7 6.1 
 
There have been many reports and much speculation about the association of 
the human coronaviruses with other diseases. Some of these associations include 
hepatitis, multiple sclerosis and newborn enteric diseases. Esper et al (2005) 
claimed in one of their studies that human coronavirus NL63 might be associated 
with Kawasaki disease, one of the most common causes of childhood vasculitis 
(Burns and Glode, 2004). They tested respiratory tract specimens of eleven 
Kawasaki Disease patients and found eight tested positive for HCoV-NL63. This 
seems like a significant discovery as the cause of this disease has eluded scientists 
for many years and many claims as to the aetiology have been made in the past. 
Unfortunately it seems that this study might have been biased and many follow-up 
studies have been done – none of which could substantiate this claim (Chang et al., 
2006; Belay et al., 2005; Ebihara et al., 2005; Shimizu et al., 2005). 
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It has however been proven that NL63 is associated with croup, bronchiolitis 
and pneumonia (Arden et al., 2005; Bastien et al., 2005; Chiu et al.,  2005; Moës et 
al., 2005; Vabret et al.,  2005; Forster et al.,  2004; Konig et al., 2004; Fouchier et al., 
2004). In fact, HCoV has been shown to be one of the three leading viruses to cause 
croup (laryngotracheitis), the other two being influenza and parainfluenza. Croup is 
characterized by a loud barking cough that may be exacerbated at night. In this 
same study it was found that 50% of patients positive for the virus also had croup 
(Forster et al., 2004; Konig et al., 2004).  
There have also been many studies that did not reflect these same statistics 
(Arden et al., 2005; Bastien et al., 2005; Moës et al., 2005; Vabret et al., 2005 
Fouchier et al.,  2004) but the reason for this was most likely the patient selection. 
Depending on the sample group, patients with croup may not have been included. 
As croup patients are very rarely admitted to hospital or subjected to disease 
investigation, studies that were hospital based would not necessarily have had 
samples from these patients (Van der Hoek et al., 2006). Nonetheless, it can still be 
said with relative certainty that HCoV-NL63 is one of the most important causes for 
this disease. 
 
1.3.3.1. Co-infections with other respiratory viruses 
Many groups have reported that the occurrence of infection with HCoV-NL63 
combined with another respiratory virus is not at all a rare event. In fact, Van der 
Hoek et al (2005) showed that this occurs in up to 50% of cases. They have also 
found that the doubly infected patients are more likely to be hospitalized, indicating 
the severity of this kind of superinfection. NL63 has been found in conjunction with 
influenza A (Chiu et al., 2005), respiratory syncytial virus (RSV) (Arden et al., 2005; 
Esper et al., 2005; Van der Hoek et al., 2005), parainfluenza (Arden et al., 2005; Van 
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der Hoek et al., 2005) and hMPV (Arden et al., 2005; Esper et al., 2005). The viral 
load of NL63 is lower in these coinfected patients than that of patients infected only 
with NL63 (Chiu et al., 2005; Van der Hoek et al., 2005). There are three possible 
explanations for this phenomenon. Firstly, the NL63 might be the initial infection that 
breaks down the immune system enough for a second infection to occur. By the time 
this second infection shows symptoms, the NL63 infection might have already been 
brought under control by the host immune system. A second option is that the two 
viruses may be in competition for the same receptor, and, lastly, the immune 
response triggered by the second respiratory virus may cause inhibition of NL63 
(Van der Hoek et al.,  2006). 
 
1.3.4. Treatment of infection 
Even though the severity of disease caused by HCoV-NL63 is generally mild 
and self-limiting, it has to be taken into account that this virus has been known to 
cause more serious disease. HCoV-NL63 infection quite often leads to 
hospitalization and was the cause of death in at least one case (Bastien et al., 2005). 
It is therefore important to develop an antiviral treatment for this virus. Some 
headway has been made in this field. There are various known inhibitors for some 
coronaviruses, all of which work by reducing replication of the virus (Pyrc et al., 
2006; Stiehm et al., 1987). To date there are four ways to successfully control 
infection with NL63: pyrimidine nucleoside analogues, HR2 domain derived peptides, 
small interfering RNAs, IV immunoglobulin and protease inhibitors. The pyrimidine 
nucleoside analogues Β-D-N4-hydroxycytidine and 6-azauridine was shown by Pyrc 
et al. (2006) to inhibit NL63 on a transcriptional level. The precise mode of action for 
this inhibition is still unclear.  
Chapter 1: Introduction 
26 
As mentioned previously, HR1 and HR2 form a six-helix bundle that enables 
the fusion of the virus and the target cell. This fusion can be inhibited by peptides 
derived from the HR2 region by interacting with the HR1 and thus blocking the 
formation of the natural HR1/HR2 complex (Pyrc et al., 2006; Bosch et al., 2004). 
Low amounts of two types of small interfering RNA, targeting HCoV-NL63, made 
cells resistant to infection as shown by Pyrc et al (2006).  RSV (Hemming et al., 
1987), Kawasaki Disease (Stiehm et al., 1987) and various other respiratory 
diseases has been shown to be treated successfully by the use of intravenous 
immunoglobulin. This proved to be the case for HCoV-NL63 as well (Pyrc et al., 
2006). A broadspectrum antiviral agent can be developed containing a protease 
inhibitor acting against Mpro. This will be effective against several coronaviruses as 
this is a very highly conserved portion of the genome and would thus be found in 
most coronaviruses. N3, an inhibitor designed by Yang et al, has indeed shown to 
have broad spectrum inhibition of Mpro enzymes (Yang et al., 2005). 
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1.4. Objectives of this Thesis 
Human coronavirus NL-63 is an emerging virus and has, as yet, not been 
characterized in great detail. No molecular studies on the structural proteins from 
HCoV-NL63 have been published. Although the main features of infection and 
replication of the other coronaviruses have been studied in detail the past few 
decades, the mechanism of infection and pathogenicty of HCoV-NL63 needs to be 
understood. In light of this, it will be endeavored to partly characterise the HCoV-
NL63 M gene by cloning it into various expression vectors and then expressing it in 
various cellular systems including bacterial cells, insect cells and mammalian cells. 
The resulting knowledge gained from these experiments could then in future be used 
for further studies into the characterization of this and other human coronaviruses. 
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2.1. In silico analysis of HCoV-NL63 M protein 
2.1.1 Predictive analysis of HCoV-NL63 M 
TMHMM Server v. 2.0 (Krogh et al., 2001) was used to search for 
transmembrane regions in the M sequence.  
2.1.2. Comparison of HCoV-NL63 M homologues  
The putative amino acid sequence of HCoV-NL63 M was compared to 
sequences in the GenBank database at the National Centre for Biotechnology by 
using the Basic Blast Search Server (Altschul et al., 1990). Identified HCoV-NL63 M-
homologues were subsequently aligned with CLUSTAL X v 1.81 (Thompson et al., 
1997) and viewed with GENEDOC software (Nicholas and Nicholas, 1997).  
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2.2. Overview of common molecular biology techniques used throughout 
Chapter 2 (Refer to Appendix C for all solutions made up for study) 
2.2.1 Reverse transcription 
Reverse transcription is a process where single stranded RNA is reverse 
transcribed into complementary DNA (cDNA) with the help of reverse transcriptase. 
RT PCR was performed by using the kit from Promega. Table 4 shows the reverse 
transcription mix and Table 5 the conditions used in this study. 
 
Table 4: Reverse transcription mix used in this study 
Component Volume 
MgCl (25mM) 4,0 μl 
10 x Buffer 2,0 μl 
dNTP’s (10mM) 2,0 μl 
RNAsin 0,5 μl 
ANIV Reverse Transcriptase (25u/µl) 0,6 μl 
Oligo (dT) primer (100μM) 1,0 μl 
HCoV-NL63 RNA (Amsterdam 1) 2,0 μl 
Nuclease free water 7,9 μl 
Final volume 20 μl 
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Table 5: Reverse transcription program conditions 
 Time Temperature 
Reverse transcription 60 min 42°C 
Deanaturation 5 min 95°C 
Extension 5 min 0°C 
 
2.2.2. Polymerase chain reaction (PCR) 
PCR is an in vitro enzymatic amplification of defined DNA sequences to 
produce a high yield of amplified target DNA. This happens under the influence of 
specifically designed primers and a thermostable DNA polymerase of Thermus 
aquaticus (Taq). The process consists of three distinct steps. The first is 
denaturation of double stranded DNA followed by annealing of the primers to their 
complementary sequences on the template. The last step is extension by 
incorporation of nucleotides under the influence of Taq polymerase. With numerous 
repetitions of this set of steps, the number of copies of the target sequence rises 
exponentially. Tables 6-8 shows the PCR mixture components, program conditions 
and PCR primers used in this study. 
 
2.2.2.1. Colony PCR 
The principle for a colony PCR is exactly the same as for a normal PCR except that 
the template DNA is taken directly from a bacterial colony growing on an agar plate. 
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A sterilised bacterial loop was touched to the desired colony and was then used to 
inoculate the PCR mix discussed above. The program stays the same bar the 
extension of the initial denaturation time to 4 minutes.  
Table 6. PCR mixture components 
Component              Volume 
 PCR Negative Control 
Template 4 μl 0 μl 
dNTP (10mM) 0,5 μl 0,5 μl 
MgCl (25mM) 1,5 μl 1,5 μl 
10 x buffer 2,5 μl 2,5 μl 
Forward primer (100μM) 1,0 μl 1,0 μl 
Reverse primer (100μM) 1,0 μl 1,0 μl 
Taq (5u/μl) 0,5 μl 0,5 μl 
Nuclease free water 14 μl 18 μl 
Final volume 25 μl 25 μl 
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Table 7. PCR program conditions 
 
 
 
 
 
 
 
 
 
Table 8. Polymerase chain reaction primers used in this study (Refer to Appendix A for vector maps) 
Primer name 
Restriction sites for 
cloning 
Vector(s) used for 
cloning 
Construct 
name 
B2Bfor1 NotI/Sal pFastBac 
XS2/XN5 
B2Brev1 XbaI pFastBac 
CMV20for2 EcoRI pFlag 
pFlag6.2 
CMV20rev2 XbaI pFlag 
M-FF-for SmfI/PmeI pFlexi Flexi2 
 
  
  Time Temp 
Initial denaturation 3 min 95°C 
3
0
 c
y
c
le
s
 
Denaturation 
Annealing  
Elongation 
45 s 
60 s 
60 s 
95°C 
45°C 
72°C 
 Final elongation 15 min 72°C 
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2.2.3. PCR product purification and extraction of nucleic acid fragments from gels 
DNA was extracted from electrophoresis gels with Promega’s Wizard SV Gel 
and PCR Clean-Up System. The same kit was also used to purify PCR products. 
The desired band was cut out of the electrophoresis gel and its weight determined. 
10 µl of Membrane Binding Solution was added for every 10 mg of the gel slice. The 
mixture was vortexed and incubated at 60°C until the gel was dissolved. The tube 
was centrifuged and contents transferred to a SV Minicolumn placed in a Collection 
tube. DNA was bound to the membrane by centrifugation and washed twice with 
Membrane Wash Solution diluted with 95% ethanol. DNA was eluted of the 
membrane with 30 µl nuclease free water. The same kit was also used to purify PCR 
products by adding equal amount of the Membrane Binding Solution to the PCR 
product and then following the steps as outlined above. 
 
2.2.4. Agarose gel electrophoresis 
Agarose gel electrophoresis is a technique used for the separation of nucleic 
acids based on charge, size and conformation. DNA is negatively charged and will 
migrate away from the negative pole through the agarose gel to the positive pole 
when the gel is placed in buffer in an electrical field. The molecules will separate out 
with the larger and more folded molecules moving slower through the gel and settling 
closer to the origin than the smaller less folded molecules that are able to move 
faster through the gel. Markers with proteins at known sizes are run on all gels as 
reference for determination of size of test DNA.  
1-2% agarose gels were made with 1 x Tris Borate EDTA (TBE) made up from 
10x TBE with distilled water. Gels were run in TBE at between 50 V and 80 V. 5-25 
µl of DNA was loaded in each well after addition of 5 µl of 6x sample loading buffer. 
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Blue/Orange Loading Dye, (Promega) contains 0.4% orange G, 0.03% bromophenol 
blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10 mM Tris-HCl (pH 7.5) and 50 mM 
EDTA (pH 8.0). The dyes allow for tracking of migration of nucleic acids through the 
gel as the xylene cyanol FF migrates at approximately 4 kb, bromophenol blue at 
approximately 300 bp and orange G at approximately 50 bp in a 0.5–1.4% agarose 
gel in 0.5X TBE. 1 kb and 100 bp DNA ladders in 1x Blue/Orange loading dye 
(Promega) were run on all gels. Ethidium bromide (10 mg/ml) from Promega was 
added to agarose gel before it set. This dye intercalates with DNA running through 
the gel and fluoresces under ultra violet (UV) light enabling visualisation of DNA 
bands.  
 
2.2.5. Restriction Endonuclease digests 
Restriction endonuclease digestion works on the principle of each enzyme 
recognising its unique palindrome and cutting it in a specific way to yield either blunt 
or sticky ends that can in turn be ligated into a designated site of a vector. This 
method was used for digestion of DNA fragments for cloning into vectors, to confirm 
presence of inserts in ligated and transformed products and for linearising vectors. 
All enzymes were obtained from Promega and generally the same protocol was 
adhered to.  All reactions were incubated at 37°C for an hour followed by the addition 
of 0.5 μl of the related enzyme and incubated for an additional hour.  Products were 
separated and retrieved from agarose gels after electrophoresis. Table 9 shows the 
restriction endonuclease mixture used for digests. 
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Table 9. Restriction endonuclease mix 
Component Volume 
Nuclease free water 2,3 μl 
Buffer  2 μl 
BSA 0,2 μl 
DNA 15 μl 
Enzyme  0,5 μl 
Final volume 20 μl 
 
 
2.2.6. Ligation 
DNA fragments of interest can be cloned into plasmids which can be    
transformed into competent bacterial cells. These bacterial cells will replicate         
the plasmids with its own DNA creating multiple clones. After replication,  
plasmids can be removed for further experimentation. For ligation, the ligation  
mix was made up (as showed in Table 10) and incubated overnight at 4°C. Only for 
ligation of DNA into KRX cells for bacterial expression, was the ligation reaction left 
at room temperature for one hour.  
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Table 10. Ligation mix 
Component Volume 
Purified DNA 16 μl 
Ligation buffer 2 μl 
T4 DNA ligase (3u/μl) 1 μl 
Vector 1 μl 
Final volume 20 μl 
 
2.2.7. Plasmid DNA preparation (Minipreps) 
Plasmid DNA of overnight cultures (approximately 14 hours) were purified 
with the Promega Wizard Plus SV Minipreps DNA Purification kit. Briefly, 5 ml of 
culture was pelleted by centrifugation. The supernatant was discarded and 250 µl 
Cell Lysis Solution was added and incubated until the solution cleared. Alkaline 
Protease was added to inactivate any endonucleases or proteins released during 
lysis that could have an adverse effect on the DNA being isolated. Neutralization 
Solution was added and suspension was cleared by centrifugation. Cleared lysate 
was transferred to a spin column and DNA bound to the membrane by centrifugation. 
The DNA was washed twice with Column Wash Solution and eluted from the 
membrane with 30 µl nuclease free water. 
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2.2.8. Freezing of mammalian and insect cells 
Cos 1 and Sf9 cells were frozen down at regular intervals to ensure constant 
supply of cells. This was achieved by adding 1 ml DMSO to 2 ml FBS and 7 ml of 
cells suspended in DMEM. Cells were then frozen at -80°C in cryovials. 
 
2.2.9. SDS-PAGE 
When determining the molecular weight of a protein, general electrophoresis will 
not suffice. This is because the charge of all the proteins running on the SDS-PAGE 
gel has to be the same. To achieve this, SDS is added to the gel. SDS is an anionic 
detergent that will linearise proteins by denaturation. It then binds to the proteins to 
give them a uniform charge. The migration of the proteins in the gel will now only be 
dependent on size. Β-mercpatoethanol is also added to the samples to aid in the 
reduction of disulphide bond in the proteins. The proteins run in a gel matrix that is 
formed by the polymerisation of acrylamide and the crosslinkage of the N’N-
methylene bisacrylamide with ammonium persulphate (APS) and N’N’N’N 
tetramethylethylene diamine (TEMED) as catalysts. 
15% SDS-PAGE gels were made up using the kit (Sigma). Discontinuous gels 
were made up to ensure all proteins start at the same point before separating. SDS 
sample buffer was added to all samples and samples were boiled at 95°C for 2 
minutes before loading 5-25 µl of the sample per well. Coloured protein markers 
were also loaded as size reference. Gels were run at 40 mA for approximately 90 
minutes. Gels were now either stained with Coomassie brilliant blue or used for 
Western Blotting.  
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2.2.10. Western Blotting 
Western blotting refers to the electrotransfer of proteins from a SDS-PAGE 
gel onto a nitrocellulose membrane. Transferred proteins are now detectable by 
using labelled antibodies specific for the relevant protein. Substrate is added for 
detection purposes. 
Before use, the nitrocellulose membrane was soaked in pure methanol and 
rinsed with distilled water. The membrane, SDS-PAGE gel, sponges and blotting 
paper was soaked in 1x running buffer for 15 minutes at RT. The sandwich was 
assembled in the holders and placed in the tank with 1x transfer buffer. Transfers 
were run at 40V for 6 hours at 4°C. Membranes were stained with Poncheau Red 
until bands appeared. This serves as confirmation that protein transfer was 
successful. After rinsing with distilled water, membranes were blocked from non-
specific antibody binding by washing in a 3% fat free milk solution for 30 minutes. 
The membrane was then incubated overnight in the primary antibody (1:5000 in 3% 
milk solution) on rollers at 4°C. Membranes were washed in PBS (with 0.5% Tween) 
for 45 minutes and then exposed to secondary antibody (1:2000 in 3% milk solution)  
for 1 hour at room temperature on rollers. The membrane was washed in PBS (with 
0.5% Tween) for 45 minutes and exposed to a colour reaction. 
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2.2.11. Coomassie blue staining  
Coomassie Blue R250 is a stain that binds non-specifically to virtually all 
proteins. It is a two step process whereby the SDS-PAGE gel is over-stained with the 
staining solution turning the entire gel blue. This is now followed by a destaining step 
which removes excess stain revealing proteins bands on a clear gel. SDS-PAGE 
gels were left in the staining solution to stain overnight (12-14hrs). Stained gels were 
destained with destaining solution until excess Coomassie was removed from the 
gels and a clear background was revealed. The destaining solutions were 
replenished several times during the process. Destained gels were dried using a gel 
drying kit from Promega. 
 
  
Chapter 2: Materials and Methods 
41 
2.3. Cloning for expression in mammalian system 
2.3.1. Plasmid construction 
The sequence encoding HCoV-NL63 M gene was amplified by PCR using 
cDNA generated by RT-PCR from genomic RNA as a template (kind gift from L Van 
der Hoek, Holland). The oligonucleotide primers used for the amplification of M were 
forward 5’-gcgaattcATGTCTAATAGTAGTGTGCCTC-3’ (sense, EcoRI site in bold 
and translational start codon underlined) and for reverse 5-
gctctagaTaAGATTAAATGAAGCAATTCTC-3’ (antisense, XbaI site in bold – no stop 
codon). PCR products were subjected to agarose gel electrophoresis.  
Following gel extraction and purification of the appropriate bands, the product 
was ligated into pGEM vector using the Promega pGEM-T Easy Vector Systems. 
Ligation reactions were transformed into competent JM109 Escherichia coli (E.coli)  
cells and transformation reactions were plated onto LB agar plates. Plates were 
incubated overnight at 37°C and white colonies were selected from the plates. 
Bacterial cells from white colonies were used as template for colony PCRs to confirm 
presence of insert. Luria Bertani (LB) broth containing Ampicillin (100 mg/ml) was 
inoculated with the white colonies and grown overnight at 37°C with agitation and 
miniprepped the following day. Constructs were digested with Xba1 and EcoR1 to 
confirm the presence of the gene of interest. Digestions were visualised on agarose 
electrophoresis gels. The full-length M gene was DNA sequenced (Inqaba Biotech) 
and the insert was verified by comparison to the existing sequence for the 
corresponding gene on Genbank (AY697422). For ligation protocols, refer to 2.2.6. 
 
 
Chapter 2: Materials and Methods 
42 
2.3.2. Transformation of ligations into pCMV-myc vector for mammalian expression 
Once the DNA fragment of interest is successfully ligated into a vector, it can 
be transformed into competent cells. Competent cells are bacterial cells capable of 
taking up naked fragments of DNA into its cytoplasm. With replication of the cell, 
these fragments will be replicated with the cell’s native DNA.  
4 μl of each ligation reaction was added to 50 μl of the competent cells. This 
was incubated on ice for twenty minutes, heat shocked at 42°C for 45 seconds, 
followed by another incubation on ice for 2 minutes. 950 μl of LB medium, 
prewarmed to 37°C, was added to the reaction and it was incubated for 90 min at 
37°C with agitation. 200 μl was spread plated onto LB agar plates (10 g/L NaCl, 5 
g/L bacto tryptone, 5 g bacto yeast extract, 5 g/L bacteriological agar)  containing 
100 μl IPTG (100 mM), 20 μl X-Gal (50 mg/ml) and 10 μl Ampicillin (100 mg/ml). The 
plates were incubated overnight at 37°C. Appropriate colonies were picked off plates 
with a sterile bacteriological loop and inoculated into LB broth containing Ampicillin 
(100 mg/ml). Cultures were grown up overnight at 37°C with agitation.  
 
2.3.3. Plasmid DNA preparation (Minipreps) 
Plasmid DNA of overnight cultures (approximately 14 hours) were purified 
with the Promega Wizard Plus SV Minipreps DNA Purification kit. Briefly, 5 ml of 
culture was pelleted by centrifugation, the supernatant discarded and 250 µl Cell 
Lysis Solution was added and incubated until the solution cleared. Alkaline Protease 
was added to inactivate any endonucleases or proteins released during lysis that 
could have an adverse effect on the DNA being isolated. Neutralization Solution was 
added and suspension was cleared by centrifugation. Cleared lysate was transferred 
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to a spin column and DNA bound to the membrane by centrifugation. The DNA was 
washed twice with Column Wash Solution and eluted from the membrane with 30µl 
nuclease free water. The products was DNA sequenced (Inqaba Biotech) and the 
insert was verified by comparison to the existing sequence for the corresponding 
gene on Genbank (AY697422) 
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2.4. Cloning for expression in Baculovirus system 
2.4.1. Plasmid construction 
The sequence encoding HCoV-NL63 M gene was amplified by PCR using 
cDNA generated by RT-PCR from genomic RNA as a template (kind gift from L Van 
der Hoek, Holland). The oligonucleotide primers used for the amplification of M were 
forward 5’-gcgaattcaATGTCTAATAGTAGTGTGCCTC-3’ (sense, EcoRI site in bold 
and translational start codon underlined) and for reverse 5-
gctctagaTTAGATTAAATGAAGCAATTCTC-3’ (antisense, XbaI site in bold and stop 
codon underlined). PCR products were subjected to agarose gel electrophoresis.  
Following gel extraction and purification of the appropriate bands, the product 
was ligated into pGEM vector using the Promega pGEM-T Easy Vector Systems. 
Ligation reactions were transformed into competent JM109 E.coli cells and 
transformation reactions were plated onto LB agar plates. Plates were incubated 
overnight at 37°C and white colonies were selected from the plates. Bacterial cells 
from white colonies were used as template for colony PCRs to confirm presence of 
insert. LB broth containing Ampicillin (100 mg/ml) was inoculated with the white 
colonies and grown overnight at 37°C with agitation and miniprepped the following 
day. Constructs were digested with Xba1 and EcoR1 to confirm the presence of the 
gene of interest. Digestions were visualised on agarose electrophoresis gels. The 
full-length M gene was DNA sequenced (Inqaba Biotech) and the insert was verified 
by comparison to the existing sequence for the corresponding gene on Genbank 
(AY697422). For ligation protocol refer to 2.2.6.  
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2.4.2. Transformation of ligations into pFastBac for baculovirus expression 
1 ng of ligated DNA reaction was added to 50 μl of DH10Bac competent cells. 
This was incubated on ice for 30 minutes, heat shocked at 42°C for 45 seconds, 
followed by another incubation on ice for 2 minutes. 950 μl of SOC medium was 
added to the reaction and it was incubated for 4 hrs at 37°C with agitation (225 rpm). 
Cells were serially diluted with SOC medium to 10-1, 10-2 and 10-3. 100 μl of each of 
these dilutions were spread onto LB agar plates containing 50 μg/ml Kanamycin, 
7 μg/ml Gentamicin, 10 μg/ml tetracycline, 40 μg/ml IPTG and 100μg/ml X-gal. 
Plates were incubated at 37°C for 48 hrs. White colonies were selected from the 
plates containing 100 – 200 colonies (blue colonies also selected to act as negative 
controls). Appropriate colonies were selected and restreaked onto fresh plates 
containing all of abovementioned antibiotics, IPTG and X-gal. Plates were incubated 
overnight at 37°C. Liquid cultures were set up from appropriate confirmed single 
white colonies (blue colonies picked as negative controls). LB broth with all 
abovementioned antibiotics were incubated overnight at 37°C with agitation (225 
rpm). 
 
2.4.3. Plasmid DNA preparation (Minipreps) 
Plasmid DNA of overnight cultures (approximately 14 hours) was purified with 
the Promega Wizard Plus SV Minipreps DNA Purification kit. Briefly, 5 ml of culture 
was pelleted by centrifugation. The supernatant was discarded and 250 µl Cell Lysis 
Solution was added and incubated until the solution cleared. Alkaline Protease was 
added to inactivate any endonucleases or proteins released during lysis that could 
have an adverse effect on the DNA being isolated. Neutralization Solution was 
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added and suspension was cleared by centrifugation. Cleared lysate was transferred 
to a spin column and DNA bound to the membrane by centrifugation. The DNA was 
washed twice with Column Wash Solution and eluted from the membrane with 30 µl 
nuclease free water. The products were then subjected to agarose gel 
electrophoresis or colony PCR for confirmation of desired insert. The products was 
DNA sequenced (Inqaba Biotech) and the insert was verified by comparison to the 
existing sequence for the corresponding gene on Genbank (AY697422) 
 
2.4.4. Cells and viruses 
Sf9 cells were cultured in Sf9 medium with addition of Penicillin/Streptomycin 
(50 units/ml penicillin and 50 μg/m streptomycin). Cells were incubated at 27°C in 
250 ml flasks. Cells were split every 2-3 days depending on confluency. Cells were 
split by mechanically dislodging it by repeatedly spraying medium over the growth 
with a pipette. When cells were released into the medium, it was split into 2 or 3 
clean flasks containing fresh media. Flasks were incubated at 27°C in order for cells 
to attach and reach confluency. The recombinant baculoviruses, containing the 
coding sequences of M, were generated by using the Bac-to-Bac™ system 
(Invitrogen). Propagation of the recombinant virus was performed according to 
standard procedures.  
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2.4.5. Transfection of Insect cells 
9 x 510 Sf9 cells were seeded out into 35 mm 6 well plates containing 2 ml of 
Sf 900 II Sfm media with penicillin/streptomycin at 0.5X final concentration (50 
units/ml penicillin and 50 μg/m streptomycin). Cells were left to attach for 60 minutes. 
Transfection solutions were prepared according to protocol and left to incubate for 45 
minutes at room temperature. Cells were gently washed with SF 900 II Sfm without 
antibiotics and media was aspirated. Lipid-DNA complexes were layered over cells 
and incubated for 5 hours at 27°C. The transfection mixture was removed, 2 ml of 
Sf 900 II Sfm media with antibiotics were added, and the plates were incubated for 
72 hours at 27°C. Virus was harvested after 72 hours incubation. 
 
2.4.6. Harvesting recombinant baculovirus P1 and P2 viral stock 
Supernatant from infected Sf9 cells were aspirated and clarified by 
centrifugation for 5 minutes at 500 x g, and clarified virus-containing supernatant was 
removed (P1 viral stock). Six well plates were prepared with 2 x 106 cells per well. 
Cells were left to attach for 1 hr at room temperature. 500 μl of P1 viral stock was 
added to each well and incubated for 48 hrs at 27oC in a humidified incubator. 
Supernatant was collected and clarified by centrifugation (500 x 5 g for 5 minutes). 
These P2 viral stocks were stored at -800C for future use. 
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2.5. Cloning for expression in bacterial system 
2.5.1. Plasmid construction 
The sequence encoding HCoV-NL63 M gene was amplified by PCR using 
cDNA generated by RT-PCR from genomic RNA as a template (kind gift from L Van 
der Hoek, Holland). The oligonucleotide primers used for the amplification of M were 
forward 5’- M-FF-for- GCGCGCGATCGCCATGTCTAATAGTAGTGTGC (sense, 
SmfI site in bold and translational start codon underlined) and for reverse 5-
gctctagaTTAGATTAAATGAAGCAATTCTC-3’ (antisense, XbaI site in bold and stop 
codon underlined). PCR products were subjected to agarose gel electrophoresis.  
Following gel extraction and purification of the appropriate bands, the product 
was ligated into pGEM vector using the Promega pGEM-T Easy Vector Systems. 
Ligation reactions were transformed into competent JM109 E.coli cells and 
transformation reactions were plated onto LB agar plates. Plates were incubated 
overnight at 37°C and white colonies were selected from the plates. Bacterial cells 
from white colonies were used as template for colony PCRs to confirm presence of 
insert. LB broth containing Ampicillin (100 mg/ml) was inoculated with the white 
colonies and grown overnight at 37°C with agitation and miniprepped the following 
day. Constructs were digested EcoR1 to confirm the presence of the gene of 
interest. Digestions were visualised on agarose electrophoresis gels. The full-length 
M gene was DNA sequenced (Inqaba Biotech) and the insert was verified by 
comparison to the existing sequence for the corresponding gene on Genbank 
(AY697422) 
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2.5.2. Transformation of ligations into pFlexi for bacterial expression 
The circular Flexi vector was digested with Flexi Enzyme Blend (SgfI and 
PmeI) to yield a linear vector into which the gene of interest could be cloned 
(Promega). The reaction was incubated at 37°C for 30 minutes after which it was 
heated to 65°C for 20 minutes to inactivate the restriction enzymes. For ligation 
method refer to 2.2.6. 
Once the DNA fragment of interest is successfully ligated into a vector, it can 
be transformed into competent cells. Competent cells are bacterial cells capable of 
taking up naked fragments of DNA into its cytoplasm. With replication of the cell, 
these fragments will be replicated with the cell’s native DNA. Constructs for bacterial 
expression was transformed into competent KRX E.coli cells from which expression 
studies were carried out. All competent cells were acquired from Promega and a 
general protocol was followed for all transformations. 
4 μl of each ligation reaction was added to 50 μl of the competent cells. This 
was incubated on ice for twenty minutes, heat shocked at 42°C for 45 seconds, 
followed by another incubation on ice for 2 minutes. 950 μl of LB medium, 
prewarmed to 37°C, was added to the reaction and it was incubated for 90 min at 
37°C with agitation. 200 μl was spread plated onto LB agar plates (10 g/L NaCl, 
5 g/L bacto tryptone, 5g bacto yeast extract, 5 g/L bacteriological agar)  containing 
100 μl IPTG (100 mM), 20 μl X-Gal (50 mg/ml) and 10 μl Ampicillin (100 mg/ml). The 
plates were incubated overnight at 37°C. Appropriate colonies were picked off plates 
with a sterile bacteriological loop and inoculated into LB broth containing Ampicillin 
(100 mg/ml). Cultures were grown up overnight at 37°C with agitation.  
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2.5.3. Plasmid DNA preparation (Minipreps) 
Plasmid DNA of overnight cultures (approximately 14 hours) were purified 
with the Promega Wizard Plus SV Minipreps DNA Purification kit. Briefly, 5 ml of 
culture was pelleted by centrifugation. The supernatant was discarded and 250 µl 
Cell Lysis Solution was added and incubated until the solution cleared. Alkaline 
Protease was added to inactivate any endonucleases or proteins released during 
lysis that could have an adverse effect on the DNA being isolated. Neutralization 
Solution was added and suspension was cleared by centrifugation. Cleared lysate 
was transferred to a spin column and DNA bound to the membrane by centrifugation. 
The DNA was washed twice with Column Wash Solution and eluted from the 
membrane with 30 µl nuclease free water. The products was DNA sequenced 
(Inqaba Biotech) and the insert was verified by comparison to the existing sequence 
for the corresponding gene on Genbank (AY697422) 
 
2.5.4.Time course studies 
150 µl of the overnight cultures were added to 150 ml LB broth with 10% 
glucose, 20% Rhamnose and Ampicillin (100 mg/ml). Flasks were incubated at 37°C 
with agitation. A time course was performed by sampling 10 ml of the growing culture 
at regular intervals – every two hours for the first twelve hour followed by twelve 
hourly intervals up to 36 hours. The bacteria in the samples were lysed using 
Promega FastBreak reagent. 10 ml of overnight cultures were spun down to pellet 
cells. 6,4 ml of supernatant was discarded and cells were resuspended. 400 µl of 
FastBreak Cell Lysis Solution (Promega) was added to resuspended cells and was 
left to lyse at room temperature for 10 minutes. Samples were centrifuged to pellet 
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the cell debris. 300 µl of SDS sample buffer was added to 20 µl of the pellet. 
Similarly, 100 µl of SDS sample buffer was added to 100 µl of the supernatant. 
Samples were boiled at 94°C for 10 minutes before running on SDS-PAGE gels.  
The gels were then subjected to Western Blotting. The primary antibody used was 
rabbit-anti-GST (1:5000) followed by the secondary antibody of goat-anti-rabbit 
(1:2000). The antibody is Horseradish peroxidase (HRP)-conjugated and therefore a 
HRP substrate containing detection agent was used to detect the protein on the blots 
with a chromagenic reaction. SDS-PAGE gels were also subjected to Coomassie 
staining.  
 
  
  
 
 
Chapter 3: Results and Discussion 
  
Chapter 3: Results and Discussion 
53 
3.1. In silico characterisation of HCoV-NL63 M protein 
The HCoV-NL63 genome produces at least six distinct subgenomic (sg) 
mRNAs, which encodes for six (6) potential ORFs. M is expressed from an ORF on 
monocistronic sg mRNA 5 (Pyrc et al., 2004). The 681 bp ORF encodes for a 
putative 25.2 kDa protein, 227 amino acids in length. A previous study of the RNA 
expression levels of the HCoV-NL63 sg mRNAs shows that excluding N, M has the 
highest expression level (Pyrc et al., 2004). In the current study, TMHMM Server v. 
2.0 (Krogh et al., 2001) and Kyte-Doolittle hydrophobicity plots (Figure 5) were used 
to search for transmembrane regions in the HCoV-NL63 M protein sequence. 
Results showed that similarly to other coronavirus M proteins, HCoV-NL63 M was a 
triple spanning membrane protein. Three transmembrane regions were found at 
amino acid position 20-36, 75-97 and 129-151 (Figure 6). Predictive analysis also 
showed that the N-terminal tail faced towards the extracellular space and the short 
76aa C-terminus tail towards the cytosolic side.  
 
 
 
 
 
 
 
 
Figure 5. Hydrophobicity plot showing 3 distinct regions >1.6 on the Kyte-Doolittle scale. Peaks 
above 1.6 on the plot indicate probable membrane spanning regions. 
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Figure 6. Predicted structure/topology of HCoV-NL63 M protein. Analysis revealed a putative 
~25.2 Da protein with three membrane spanning regions at amino acid positions 20-36, 75-97 and 
129-151.   
 
3.1.1. Comparison of HCoV-NL63 M homologues  
The putative amino acid sequence of HCoV-NL63 M was compared to 
sequences in the GenBank database at the National Centre for Biotechnology by 
using the Basic Blast Search Server (Altschul et al., 1990). Identified HCoV-NL63 M-
homologues were subsequently aligned with CLUSTAL X v 1.81 (Thompson et al., 
1997) and viewed with GENEDOC software (Nicholas and Nicholas, 1997). The M 
protein of HCoV-NL63 was found to be more similar to M proteins of other Group I 
coronaviruses (Figure 7). 
Extracellular space 
Cytosolic space 
Chapter 3: Results and Discussion 
55 
 
Figure 7. Alignment of the amino acid sequences of HCoV-NL63 M and selected coronavirus M 
proteins. Identified homologues were aligned; shading indicates conserved regions and gaps were 
introduced to align sequences. Conserved regions (>10 aa) indicated by solid bars and consensus 
sequence shown below the aligned sequences. Three levels of shading shown. 
 
The M amino acid sequences aligned (Figure 7 and Table 11) were (HCoV-
NL63), Human coronavirus NL63 Amsterdam 1 M; (HCoV-229E), Human 
coronavirus 229E CCU T935; (PEDV) Porcine epidemic diarrhoea virus DX; (TEGV), 
Transmissible gastroenteritis virus BW021898B; (CCoV), Canine coronavirus type I 
Elmo/02; and (FCoV), Feline coronavirus FCoV/NTU2/R/2003.  
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Table 11. Comparison of HCoV-NL63 M amino acid sequence to homologues from selected Group I 
coronavirus isolates. Identity values (%) are shown in bold and similarity values (%) are shown in 
italics. 
 
 
The amino acid sequence of HCoV-NL63 M was shown to be most similar to 
human coronavirus 229E M (Table 11; 49% identity and 49% similarity). The 
comparative analysis showed two (2) regions ≥ 10 amino acids that were well 
conserved between the M homologues (Figure 7). The functions, if any, of these 
regions are not known, but could warrant further research. 
 
 
 
TGEV 
 
FCoV 
 
HCoV-NL63 
 
HCoV-229E 
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84% 
87% 
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82% 
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HCoV-NL63 
   
 
49% 
49% 
27% 
39% 
      
HCoV-229E 
    55% 
80% 
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Coronavirus M proteins are N-glycosylated, triple-spanning membrane 
proteins (de Haan et al., 2003). The TGEV M protein has been shown to have 
interferogenic activity. Mutations in the ectodomain causing disruption of N-
glycosylation, down-regulates this interferogenic activity (Laude et al., 1992). The 
coronavirus M protein also plays a role in virion assembly, as well as in interaction 
with host cells and therefore infectivity. The formation of new virions is dependent on 
two processes; the one is the assembly of the nucleocapsid and the other, the 
assembly of the envelope. The M protein plays an essential role in both these 
processes by directing the formation of the envelope, as well as providing the basis 
for the attachment of the nucleocapsid to enable budding (de Haan et al., 2000).  
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3.2. Cloning for expression in mammalian system 
The vector used for the cloning of M for expression in a mammalian cell 
system, was pCMV-Myc Mammalian Expression Vector (Clontech). The pCMV-Myc 
vector is able to express N-terminal c-Myc tagged. This tag is known to be decidedly 
immunogenic. The vector contains an Ampicillin resistance gene for selection of 
successfully ligated and transformed constructs in competent E.coli, a multiple 
cloning site into which the gene of interest can be cloned, and a SV40 
polyadenalation signal. Under the influence of the promoter PCMV IE from 
cytomegalovirus, the proteins will be expressed at high levels in mammalian cells.  
The initial step involved the generation of 1st strand cDNA from viral RNA 
using RT-PCR. Next, PCR amplification was used to amplify the HCoV-NL63 M gene 
from the cDNA using specific primers. PCR primers were designed with EcoRI and 
XbaI restriction sites for unidirectional cloning of the insert into the vector, and also to 
clone the insert “in-frame” with the N-terminal myc-tag nucleotide sequence in the 
vector.  
 
Figure 8. PCR of the full-length M gene from complete HCoV-NL63 genome. Lane 1: 100bp DNA 
ladder; Lane 2: Amplification of M from cDNA; Lane 3: Negative PCR control; Lane 4: 1Kb DNA 
ladder. 
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Lane 2 (Figure 8) showed the amplification product (~700 bp), that 
corresponded to the expected size of the M gene (~681bp). The result showed that 
the viral RNA genome was successfully transcribed from RNA to DNA during the 
reverse transcription step.  Lane 3 showed the negative PCR control, i.e. no cDNA 
added to the PCR reagent mixture; no amplification products were visible in this lane 
indicating that no contamination took place during the preparation or running of the 
PCR. Next, the product was ligated into the pGEM vector to generate pGEM-M, 
followed by transformation into competent JM109 E. coli cells for blue-white colony 
selection. The presence of white colonies on the test plate indicated successful 
ligation of the gene of interest into the plasmid (pGEM) as recombinant clones will 
disable bacterial cells from digesting the IPTG in the presence of X-gal. This is due 
to the disruption of the β-galactosidase gene by the insertion of the gene of interest 
into the vector. The unsuccessfully ligated plasmids will enable the bacterial cells to 
use the IPTG as substrate and form the blue colonies in the presence of the X-Gal 
as the β-galactosidase gene was not disrupted. 
Transformed plates of pGEM-M showed various white colonies (Figure 9a) of 
which four (4) were picked and used as template in a colony PCR to tentatively 
confirm the presence of the full-length M gene (Figure 11) based on size of the 
insert. The absence of growth on the negative control plate (Figure 9b) confirmed the 
ampicillin used in the plates was active. This affirms that all colonies present on the 
test plate contained plasmids that were effectively transformed into the competent 
JM109 E.coli cells; this is true because the plasmid confers Ampicillin resistance to 
the bacteria. The bacterial cells will therefore not be able to grow in the presence of 
the Ampicillin on the plate unless it contains the plasmid. The presence of the M 
gene in pGEM was confirmed by colony PCR amplification of products ~700bp in 
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size, corresponding to the expected size of 681bp for M (Figure 10, Lanes 3-6). No 
bands are visible in this lane indicating that no contamination took place during the 
setup or running of the PCR. This serves as proof that the bands seen in the test 
lanes are valid positive results and not contamination. 
Cloning into pGEM was done to facilitate the confirmation of the nucleotide 
composition of the amplicon by sequencing (INQABA Biotech). When colonies were 
screened for the correct insert size by colony PCR (pGEM-M1, pGEM-M2, pGEM-
M3 and pGEM-M4), these colonies were also inoculated into LB broth containing 
ampicillin and cultured overnight for plasmid extraction. Since all colonies were 
tentatively positive for insert by colony PCR, two constructs (pGEM-M1 and pGEM-
M4) were selected for cloning M into the mammalian expression vector.  
 
 
Figure 9.  Agar plate of transformation of pGEM constructs into JM109 E.coli competent cells. (a) 
JM109 cells transformed with pGEM-M plated onto LB plates containing ampicillin; (b) Negative 
control. JM109 plated onto LB plates containing ampicillin.  
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Figure 10.  Colony PCR of M ligated into pGEM and transformed into JM109 E. coli. Lane 1: 100bp 
DNA ladder; Lane 2: Negative PCR control; Lanes 3-6 – Colony PCR of white colonies; Lane 7: 1kb 
DNA ladder. 
 
Plasmid DNA was extracted from these cultures and subsequently restriction 
enzyme digested with XbaI and EcoRI to confirm insert size (Figure 11).  In the 
meantime, pGEM-M1 and pGEM-M4 DNA were submitted for sequence verification 
(results not shown); sequencing results showed nucleotide sequences of the 
amplicons that were identical to the HCoV-NL63 M sequence on the NCBI database. 
For the purposes of this project, both inserts were selected for cloning into the 
pCMV-myc vector to generate pCMV-myc-M1 and pCMV-myc-M4. 
Briefly, inserts digested with XbaI and EcoRI from pCMV-myc-M1 and pCMV-
myc-M4 were gel purified and ligated into the compatible sites of pCMV-myc vector. 
This was followed by transformation into JM109 E.coli supercompetent cells 
(Promega) for blue-white selection. Several white colonies were picked from the agar 
plates and were used as template in a colony PCR to confirm correct insert size 
(data not shown). 
One colony PCR-positive for pCMV-myc-M1 and pCMV-myc-M4 were 
selected for overnight growth in LB broth with ampicillin. Plasmid DNA was extracted 
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and subjected to a restriction enzyme digestion with XbaI and EcoRI to further 
confirm the presence of the gene of interest. Lanes 1 and 2 (Figure 12) each showed 
two bands; the lower band at ~700 bp was that of the M gene that was cut out of the 
vector and the top band represents the vector at approximately ~4 kb. These 
samples were therefore confirmed to have the insert cloned into the vector. Lane 3 
was the negative control. There were no bands present in the lane, indicating that no 
contamination took place during the digestion and that the results were valid. 
 
Figure 11. Restriction enzyme digestion of pGEM-M1 and pGEM-M4. Lane 1: 100bp DNA ladder; 
Lanes 2: pGEM-M1; Lane 3: pGEM-M4; Lane 4: Negative control; Lane 5: 1kb DNA ladder 
 
Figure 12.  Restriction enzyme digests of pCMV-myc constructs. Lane 1: pCMV-myc-M1;  Lane 2: 
pCMV-myc-M4; Lane 3: Negative control; Lane 4: 100bp DNA ladder. 
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3.3. Cloning for expression in Baculovirus system 
Baculovirus expression technologies have made significant advances in the 
past 25 years, leading to them becoming more popular and quite versatile for the 
production of recombinant proteins (Freisen and Miller, 2001; Kost and Condreay 
1999; Miller, 1997; Possee, 1997; O’reilly et al., 1992; Luckow and Summers, 1988). 
In these systems, a recombinant protein is created, processed, modified and 
targeted to its appropriate subcellular location as it would have been in the original 
cell (Kitts et al., 1990). These proteins are expressed at high levels and are also 
functionally similar to the original parent proteins. A very wide variety of genes have 
been expressed in this way including genes from viruses, mammals, fungi and plants 
(King and Possee, 1992; O’reilly et al., 1992; Luckow, 1991; Murhammer, 1991; 
Maeda, 1989; Luckow and Summers, 1988;). In the present study, the Bac-2-Bac 
system was used for cloning of the full-length HCoV-NL63 M gene for expression in 
insect cells.  
The Bac-to-Bac cloning system has a number of features distinguishing it 
from other baculovirus cloning systems. One of the most attractive being the 
significantly reduced time (<2 weeks) it takes to create purified recombinant genes. 
This is because the recombinant DNA is never mixed with the original parent DNA 
and therefore there is no need for repeated plaque purification procedures. This 
separation of recombinant and non-recombinant DNA is achieved by the insertion of 
the lacZ gene into the vector allowing for blue white colony selection on agar plates. 
Single and multiple genes can easily be integrated into baculoviruses using 
commercially available plasmids and can be used for Gateway cloning. These 
characteristic make the Bac-to-Bac system the most efficient system for multiparallel 
gene expression. The simplicity and relative speed of the system allows for greater 
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throughput with the amplification of multiple viruses at a time (Hunt, 2005). This 
system is also suited for expression of proteins for structure and function studies 
(Invitrogen). 
In this study, the first step involved PCR amplification of the HCoV-NL63 M 
gene from the cDNA generated earlier. Lane 3 (Figure 13) showed the amplification 
product (~700 bp), that corresponded to the expected size of the M gene (~681bp). 
The result showed that the viral RNA genome was successfully transcribed from 
RNA to DNA during the reverse transcription step.  Lane 2 depicted the negative 
control; no amplification products were visible in this lane indicating that no 
contamination took place during the setup or running of the PCR.          
            
Figure 13. 1% Agarose gel electrophoresis of PCR product generated with M-specific primers using 
HCoV-NL63 cDNA as template. Primers incorporated restrictions enzyme sites for cloning into Bac-2-
Bac system. Lane 1: 100bp DNA ladder; Lane 2: Negative control; Lane 3: PCR of M; Lane 4: 1kb 
DNA ladder. 
 
In order to verify the nucleotide sequence of the amplicon, the product was 
then ligated into the pGEM vector to generate pGEM-M, followed by transformation 
into competent JM109 E. coli cells. Transformed plates of pGEM-M showed various 
white colonies (results not shown) that were picked and used as template in a colony 
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PCR to tentatively confirm the presence of M.  The presence of the M gene in pGEM 
was confirmed by amplification products ~700bp in size, corresponding to the 
expected size of 681bp for M (Figure 14, Lanes 2-4).  
 
Figure 14. 1% Agarose gel electrophoresis of PCR product generated from colony PCR of pGEM-M 
transformed into JM109 E.coli.  Lane 1: 100bp DNA marker; Lane 2: pGEM-M1; Lane 3: pGEM-M2; 
Lane 4: pGEM-M3; Lane 5: Negative PCR control; Lane 6: 1kb DNA ladder. 
 
At the same time, colonies selected for colony PCR (pGEM-M1, pGEM-M2 and 
pGEM-M3) were inoculated into LB broth containing ampicillin and cultured overnight. 
Since all colonies were tentatively positive for insert by colony PCR, plasmid DNA 
was extracted from all three cultures and subsequently restriction enzyme digested 
with XbaI and EcoRI to confirm insert size (Figure 15). All three pGEM-M constructs 
were submitted for sequence verification (results not shown) and pGEM-M2 was 
selected for cloning into the pFastBac vector to generate pFastBac-M.  
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Figure 15. XbaI and EcoRI restriction enzyme digestion of M from the three positive pGEM-M 
constructs identified in Figure 14.  Lane 1: 100bp DNA ladder; Lane 2: pGEM-M1 restriction enzyme 
digest; Lane 3: pGEM-M2 restriction enzyme digest; Lane 4: pGEM-M3 restriction enzyme digest; 
Restriction enzyme digests of pGEM-M constructs. 
 
The XbaI and EcoRI-digested and gel purified M2 insert was now ligated into 
the pFastBac vector to generate pFastBac-M and was then transformed into 
DH10Bac competent E.coli cells. In our system, the expression of M would be 
regulated by the Autographica californica multiple nuclear polyhedrosis virus 
(AcMNPV) polyhedron (PD). The DH10Bac E.coli cells contained a bacmid 
(baculovirus shuttle vector) with a mini-attTn7 target site and a helper plasmid 
(pMON7124). The bacmid (bMON14272) is 136kb and contains a low-copy number 
mini-F replicon, Kanamycin resistance marker and a segment of DNA coding for the 
LacZα peptide from a PUC-based cloning vector. This is the site into which the 
bacterial transposon Tn7 attachment site (mini-attTn7) has been inserted. The helper 
plasmid (13.2kb) provides the Tn7 transposition function in trans (Barry, 1988) and 
encodes the necessary transposase as well as conferring tetracycline resistance. 
When the pFastBac vector has been transformed into the DH10Bac cells, 
transposition occurs (under influence of transposase supplied by helper plasmid) 
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between the mini-attTn7 target site on the bacmid and the mini-Tn7 element on the 
pFastBac vector to form the recombinant bacmid.  
Plates of pFastBac-M transformed DH10Bac cells showed various white 
colonies, of which four (4) were picked with a toothpick and used as template in a 
colony PCR with M-specific primers to confirm the presence of the M gene (Figure 
16). At the same time, the selected colonies were cultured overnight and 
recombinant bacmid DNA extracted. 
 
Figure 16. Colony PCR of the M gene from four (4) selected white colonies. Lanes 1–4: Tests; Lane 
5: Negative PCR control; Lane 6: 1Kb DNA ladder. 
 
The bacmid will propagate in the E.coli as a large plasmid and will lend the 
bacteria resistance to Kanamycin as well as complementation to a LacZ deletion on 
the chromosome. This last characteristic enables the cells to form blue colonies in 
the presence of a chromagenic substrate such as X-gal or Bluo-gal, together with 
IPTG. As it is difficult to analyse the recombinant bacmid by the more conventional 
method of restriction by endonucleases, the presence of the recombinant gene was 
confirmed by PCR and agarose gel electrophoresis (Figure 17). Lane 2 showed the 
complete product, amplified with both the M13 forward and reverse primers, i.e.  the 
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gene of interest (681bp), plus the bacmid (273 bp) and transposed vector (1980 bp) 
at 2934 bp. This was the expected size as shown in Figure 18.  
 
Figure 17.  Gel of PCR of recombinant bacmid. Lane 1: 1kb DNA ladder; Lane 2: Product amplified 
with M13-forward and -reverse primers; Lane 3: Product amplified with the M13-forward primer and 
the gene-specific reverse primer; Lane 4: Product amplified with the M13-reverse primer and the 
gene-specific forward primer; Lane 5: Product amplified with gene specific primers; Lane 6: Bacmid 
only; Lane 7: 100bp marker. 
Lane 3 showed the product when amplified with the M13 forward primer and the 
gene specific reverse primer yielding a product of 2331bp; this represented the 
bacmid + pFastBac + M gene. Lane 4 showed the product amplified with the M13 
reverse primer and the gene specific forward primer yielding a product of 
approximately 1284bp; this represented bacmid + pFastBac + M gene. Lane 5 
showed the insert amplified with gene specific primers at 681bp. Finally, Lane 6 
showed the bacmid only at 300bp (Figure 17 and 18). From these results it can be 
concluded that the M gene was successfully cloned into the pFastBac vector and 
consequently into the bacmid and was now ready to be expressed in Sf9 cells for 
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expression studies. The recombinant bacmid was used to infect Spodoptera 
frugiperda Sf9 insect cells using Cellfectin (Invitrogen). P1 recombinant baculovirus 
stock was obtained and cells were re-infected to generate P2 viral stock as 
discussed in the Materials and Methods section. Both P1 and P2 viral stocks were 
frozen and stored at -800C for future use. The titer of these viral stocks will be 
determined in future. However, M-specific antibodies are currently being raised as 
part of another project. These antibodies will be used to screen our P1 and P2 viral 
stocks for expression of full length HCoV-NL63 M protein by Western Blot and 
immune- detection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Diagrammatic representation of expected fragment sizes after gel electrophoresis of PCR 
of recombinant bacmid. 
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3.4. Cloning for expression in Bacterial system 
Many vectors are available within the Flexi range. For this study, the pFN2A 
(GST) vector was chosen for protein expression. This vector is especially designed 
to express amino terminal GST-fusion proteins in bacteria. The GST tag can be used 
to detect and even purify expressed protein. The tag can also be cleaved off the 
expressed protein with TEV protease. For protein expression, this vector requires the 
use of a competent E.coli strain that expresses T7 RNA polymerase like KRX E.coli.   
KRX E.coli (Promega) was the cloning strain of choice for various reasons. 
Some of these include the lack of common nucleases present in other E.coli strains, 
partially defective restriction systems, mutations to prevent proteolysis of the 
overexpressed protein and mutations to limit undesirable recombinations. The 
system is compatible with various commercially available vectors that makes use of 
the T7 promoter (e.g. Flexi, as in the case of this study), making it extremely user 
friendly. Another advantage is that recombinant protein expression can be precisely 
controlled. This is due to the presence of a T7 RNA polymerase gene which is driven 
by the rhamnose promoter rhaPBAD. This type of T7 RNA polymerase-based 
system enjoys wide use because the promoter is totally independent of the E.coli 
RNA promoters, and the fact that the T7 polymerase’s elongation rate is about 5x 
that of the E.coli RNA polymerase. The rhaBAD gene is replaced by the T7 RNA 
polymerase gene so that the rhaBAD promoter will control its expression. The 
promoter is activated by rhamnose and suppressed by glucose. Adding controlled 
amounts of these substances to the growth medium therefore lend excellent control 
of recombinant protein production by the researcher. 
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Figure 19. Agarose gel of PCR of the M gene for expression in bacteria. Lane 1: 100bp DNA ladder; 
Lane 2: Negative PCR control; Lane 3: PCR of full-length M gene; Lane 4: 1kb DNA ladder. 
 
The gene of interest (M gene) was amplified from the 1st copy DNA with gene 
specific primers for unidirectional cloning into the vectors. Primers were designed to 
append the SgfI and PmeI restriction enzyme sites to the amplification product. 
These enzymes are the most infrequent cutting enzymes in human cDNA (98%) and 
also rarely cut in other organisms. The SgfI cut site is upstream of the start codon of 
the protein coding region. This enables expression of untagged proteins as well as N 
terminal tagged proteins. The PmeI site contains the stop codon for the protein 
coding region and adds a Valine residue to the carboxy terminus of the protein. The 
reading frame and the orientation of the insert are maintained by these two enzyme 
cut sites. The amplification product was separated on a 1% Agarose gel (Figure 19) 
by electrophoresis; Lane 1 and 4 showed the 100bp and 1kb marker respectively. 
Lane 3 showed the amplification product at ~700bp, which corresponded to the 
expected size of the M gene at ~681bp. First, the PCR product was ligated into the 
pGEM vector (for ease of sequencing) and transformed into competent JM109 E.coli 
cells. Following incubation overnight, two white colonies were picked and used as 
template in a colony PCR (Figure 20). At the same time, these colonies were 
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cultured overnight, plasmid DNA extracted by the mini-preparation method and 
sequenced to determine the nucleotide sequence (INQABA Biotech). Both construct 
sequences were determined to be identical to the HCoV-NL63 M gene sequence at 
the NCBI database (results not shown) and therefore one was selected for all 
subsequent cloning.   
Next the plasmid DNA was enzyme digested with SgfI and PmeI and the 
insert was gel purified (Promega) and ligated into compatible sites of the pFlexi 
vector, generating pFlexi-M. This construct was transformed into KRX E. coli cells 
and plated on LB agar plates containing ampicillin (Figure 21). 
 
Figure 20.  Agarose gel of colony PCR of insert transformed into JM109 E.coli. Lane 1: 1kb DNA 
ladder; Lane 2 and 3: Colony PCRs; Lane 4: Negative PCR control; Lane 5: 100bp DNA ladder. 
 
All colonies on plate (b) (Figure 21) should be successfully ligated and transformed 
recombinants as the flexi vector contained the lethal barnase gene which was 
replaced by the M. Additionally, the vector also conferred antibiotic resistance to the 
competent cells which would otherwise be unable to grow in the presence of the 
Ampicillin that was added to the plates. Two colonies were picked and grown 
overnight in LB broth containing ampicillin. Plasmid DNA was extracted and 
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constructs pFlexi-M1 and pFlexi-M2 was digested with SgfI and PmeI to confirm the 
presence of full-length M. 
 
 
Figure 21. Agar plates of transformation of M into KRX E.coli cells.  (a) Negative control; (b) Test 
plate. 
 
The gene of interest was successfully digested from the vector as can be seen by 
the bands at approximately 700 bp and the vector at approximately 3kb (Figure 22, 
lanes 2 and 3).  
 
 
 
Figure 22. Restriction enzyme digests of pFlexi-M with restriction enzymes SgfI and PmeI. Lane 1: 
1kb DNA ladder; Lanes 2: pFlexi-M1 enzyme digest; Lane 3: pFlexi-M2 enzyme digest; Lane 5: 100bp 
DNA ladder. 
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Figure 23. Western Blots of GST-M protein expressed by KRX E.coli over a 36 hour time course. (a) 
Supernatant; (b) Pellet. 
Subsequently, pFlexi-M1 was selected for expression studies. A 36 hour 
protein expression time course was run to access the expression characteristics of 
the M protein in the KRX E.coli. Figure 23 shows the expression profile of GST-M 
over a 36 hour period. Cells were harvested, lysed and total proteins were separated 
on SDS PAGE and Western Blotted. Both pellet and supernatant samples were 
subjected to immunoblotting with anti-GST antibody. The blot of supernatant sample 
showed virtually no bands at all. This is indicative of the M protein not being present 
in the supernatant of the cell (Figure 23 a).  The Western blot of the pellet sample 
showed that M expression was detected approximately 6-8 hrs after protein 
induction, with optimal expression levels seen at 24 hrs; expression levels then 
increased through to 36 hrs. The GST-M protein was detected as a 50 kDa protein; 
i.e. a 25 kDa GST tag appended to the 25 kDa M protein. The anti-GST antibody 
specifically detected the M fusion protein. As expected, since M is an integral 
membrane protein, GST-M was detected in the pellet portion of the cell lysate 
(Figure 23b); this consisted of all membrane structures. Due to the nature of the 
antibody used, the IgG Heavy and IgG light chains were also detected on the blot 
IgG Heavy   
IgG Light Chain 
GST-M  
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(Figure 23b).  M was detected as ~25 kDa protein (excluding the ~25 kDa) GST 
fusion tag), which corresponded to the predicted protein size. The predicted size 
excluded any posttranslational modification of M. It was therefore evident that the 
HCoV-NL63 M protein was not posttranslationally modified in this system. In order to 
study any modification, processing or function of M, studies need to done in a 
system that allows for the proper processing of the proteins, such as a mammalian 
and/or baculovirus system. 
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The complete HCoV-NL63 RNA genome was transcribed to 1st strand cDNA 
using random poly-A primers. The HCoV-NL63 M gene was amplified from the cDNA 
using different gene specific primer sets for cloning into different expression vector 
systems. The full-length M gene was cloned into vectors for expression in bacterial, 
baculovirus and mammalian expression systems; all sequences were verified by 
double stranded sequencing of constructs.  
 
4.1. Mammalian expression 
The pCMV-Myc vector is able to express N-terminal c-Myc tagged proteins. 
This tag is known to be decidedly immunogenic. The vector contains an Ampicillin 
resistance gene for selection of ligated and transformed constructs in competent 
E.coli. The vector also contains a multiple cloning site into which the gene of interest 
can be cloned and a SV40 polyadenalation signal. Under the influence of the 
promoter PCMV IE from cytomegalovirus, the proteins will be expressed at high levels 
in mammalian cells. 
1st strand cDNA was generated from viral RNA by RT-PCR. The full-length M 
gene was PCR amplified for unidirectional cloning into the pCMV-Myc vector “in-
frame” with the c-myc tag sequence. The amplified M gene was cloned into the 
pGEM-T-Easy vector for sequencing. Sequence-verified inserts were digested from 
the pGEM vector and cloned into compatible sites of the pCMV-Myc vector.  
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4.2. Baculovirus expression (Refer to Appendix B) 
The Bac-to-Bac system is a rapid, easy and efficient system to use for the 
generation of recombinant baculoviruses (Ciccarone et al., 1997). The system is 
based on the site-specific transposition of an expression plasmid into a baculovirus 
shuttle vector (bacmid) propagated in E. coli (Luckow et al., 1993). The system uses 
the site specific transposition properties of the Tn7 transposon to simplify and 
enhance the process of generating recombinant bacmid DNA. Expression of the 
recombinant gene is under the influence of either the Autographica californica 
multiple nuclear polyhedrosis virus polyhedron (AcMNPV-PH) or p10 (AcMNPV-
P10), which are genes that are highly transcribed in the late stages of infection. This 
leads to high expression levels in the infected cells which in turn results in proteins 
that are functionally similar to the wild-type proteins (King and Possee, 1992; O’reilly 
et al, 1992; Luckow, 1991; Murhammer, 1991; Maeda, 1989; Luckow and Summers, 
1988; Miller, 1988).  
Even though Bac-to-Bac is an extremely efficient system for gene expression 
in baculoviruses, it has to be said that it also has some disadvantages.  Studies have 
shown that recombinant baculovirus obtained via bacmid transposition as opposed 
to the more traditional homologous recombination method, tends to be inherently 
unstable and may be spontaneously deleted from the genome upon increased 
passaging of the insect cells (Pijlman et al., 2003). This should however not create a 
problem in the routine research laboratory as the number of passages required for 
this deletion tends to be quite high.  
The M gene was amplified from 1st strand cDNA for the expression in a 
baculovirus expression system. The full-length HCoV-NL63 M gene was cloned into 
the pGEM-T-Easy shuttle vector to facilitate sequencing of the insert. The sequence 
Chapter 4: Conclusion 
79 
verified insert was enzyme digested from the pGEM-M construct. It was then cloned 
into the pFastBac vector followed by transformation into competent DH10Bac E.coli 
cells. P1 and P2 viral stocks were generated and stored for future use. Currently, M-
specific antibodies are being generated that will be used to screen the P1 and P2 
virus stock lysates for expression of the full-length M protein.  
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4.3. Bacterial expression 
The Flexi vector system (Promega) is an extremely suitable vector system to 
use for bacterial protein expression. It is a directional cloning system making use of 
two extremely rare restriction endonucleases SgfI and PmeI. These enzymes are the 
most infrequent cutting enzymes in human cDNA (98%) and also rarely cut in other 
organisms. The SgfI cut site is upstream of the start codon of the protein coding 
region. This enables expression of untagged proteins as well as N terminal tagged 
proteins. The PmeI site contains the stop codon for the protein coding region and 
adds a Valine residue to the carboxy terminus of the protein. The reading frame and 
the orientation of the insert is maintained by these two enzyme cut sites.  
The vector also contains a barnase gene which is a gene coding for 
ribonuclease. This gene is lethal and needs to be replaced by the gene of interest to 
enable the clone to survive. This acts as a positive control for ligation as only 
successfully ligated clones will survive. This eliminates the need for blue/white 
colony selection and screening for successfully ligated colonies. Another feature 
used to act as a positive control is the presence of a antibiotic resistance gene 
(either Kanamycin or Ampicillin depending on the vector used). Only the colonies 
that have been successfully ligated and transformed would be able to survive on 
bacterial plates containing these antibiotics. This system does not need multiple 
amino acids to be appended to the amino- or carboxy termini of the gene of interest 
as are required by more traditional site specific recombination systems. 
The HCoV-NL63 M gene was amplified from 1st strand cDNA, cloned into 
shuttle vector pGEM-T-Easy and finally cloned into the pFlexi vector to append a 
GST at the N-terminus of the M protein. The pFlexi-M construct was transformed into 
competent KRX E.coli cells and a 36hr time course expression profile was 
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performed; expression of the GST-M fusion protein was first detected from 
approximately 8 hours with optimum expression levels reached after 24 hours. As 
the majority of the GST-M proteins were seen in the pellet after cell lysis, and only a 
minimal portion seen in the supernatant, it was concluded that the HCoV-NL63 M 
protein was expressed on the membrane of the host cell. 
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Vectors used in this study: 
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Solutions used: 
1. 4x stacking gel buffer 
60,5g Tris in 1000ml distilled water at a pH of 6,8. 
 
2. 4x resolving gel buffer 
181,5g Tris in 1000ml distilled water at a pH of 8,8. 
 
3. 10 x running buffer 
30g Tris, 144,0g glycine and 10,0g SDS in 1000ml distilled water at a pH 8,3 
 
4. 10% SDS stock solution 
10g SDS in 100ml distilled water. 
 
5. 2x SDS-PAGE sample buffer 
2ml   4x stacking gel buffer 
1,6 ml  Molecular grade glycerol 
3,2ml   10% SDS 
0,8ml   β-mercaptoethanol 
0,4ml   1% Bromophenol blue 
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6. Separating/resolving gel (15%) 
3,15ml  Distilled water 
3,75ml  Acryl/bisacrylamide 
2,5ml   4x resolving buffer 
0,1ml   10% SDS 
10µl   TEMED 
0,5ml   APS 
 
7. Stacking gel 
2.86ml  Distilled water 
0,3ml   Acryl/bis acrylamide 
0,5ml   Stacking gel buffer 
0,04ml  10% SDS  
10µl   TEMED 
0,3ml   APS 
 
8. Transfer buffer (10x) 
30,3g Tris and 144,1g glycine in 1000ml distilled water 
Made up to 1x with distilled water and 20% methanol for transfers. 
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9. 3% Milk blotting solution 
3g   Fat Free milk powder (Biorad) 
100ml  PBS (with 0,5% Tween) 
 
10.  Coomassie Brilliant Blue R250 staining solution 
 0,25g  Coomassie Brilliant Blue R250 powder 
90ml  MetOH:H2O (1:1 v/v)  
10ml  Glacial acetic acid 
 
11.   Coomassie Brilliant Blue Destaining Solution 
90ml  MetOH:H2O (1:1 v/v)  
10ml  Glacial acetic acid 
10%  Glycerol 
 
